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A B S T R A C T
Background
Alcoholic hepatitis is a form of alcoholic liver disease characterised by steatosis, necroinflammation, fibrosis, and complications to the
liver. Typically, alcoholic hepatitis presents in people between 40 and 50 years of age. Alcoholic hepatitis can be resolved if people abstain
from drinking, but the risk of death will depend on the severity of the liver damage and abstinence from alcohol. Glucocorticosteroids
have been studied extensively in randomised clinical trials to assess their benefits and harms.However, the results have been contradictory.
Objectives
To assess the benefits and harms of glucocorticosteroids in people with alcoholic hepatitis.
Search methods
We identified trials through electronic searches in Cochrane Hepato-Biliary’s (CHB) Controlled Trials Register, CENTRAL, MED-
LINE, Embase, LILACS, and Science Citation Index Expanded. We looked for ongoing or unpublished trials in clinical trials registers
and pharmaceutical company sources. We also scanned reference lists of the studies retrieved. The last search was 18 January 2019.
Selection criteria
Randomised clinical trials assessing glucocorticosteroids versus placebo or no intervention in people with alcoholic hepatitis, irrespective
of year, language of publication, or format. We considered trials with adults diagnosed with alcoholic hepatitis, which could have been
established through clinical or biochemical diagnostic criteria or both. We defined alcoholic hepatitis as mild (Maddrey’s score less than
32) and severe (Maddrey’s score 32 or more). We allowed cointerventions in the trial groups, provided they were similar.
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Data collection and analysis
We followed Cochrane methodology, performing the meta-analyses using Review Manager 5. We presented the results of dichotomous
outcomes as risk ratios (RR) and of continuous outcomes as mean difference (MD), with 95% confidence intervals (CI). We used
both the fixed-effect and the random-effects models for meta-analyses. Whenever there were significant discrepancies in the results, we
reported the more conservative point estimate of the two. We considered a P value of 0.01 or less, two-tailed, as statistically significant
if the required information size was reached for our three primary outcomes (all-cause mortality, health-related quality of life, and
serious adverse events during treatment) and our post hoc decision to include analyses of mortality at more time points. We presented
heterogeneity using the I² statistic. If trialists used intention-to-treat analysis to deal with missing data, we used these data in our
primary analysis; otherwise, we used the available data. We assessed the bias risk of the trials using bias risk domains and the certainty
of the evidence using GRADE.
Main results
Sixteen trials fulfilled our inclusion criteria. All trials but one were at overall high risk of bias. Fifteen trials (one of which was an abstract)
provided data for analysis (927 participants received glucocorticosteroids and 934 participants received placebo or no intervention).
Glucocorticosteroids were administered orally or parenterally for a median 28 days (range 3 days to 12 weeks). The participants were
between 25 and 70 years old, had different stages of alcoholic liver disease, and 65% were men. Follow-up, when reported, was up to
the moment of discharge from the hospital, until they died (median of 63 days), or for at least one year. There was no evidence of effect
of glucocorticosteroids on all-cause mortality up to three months following randomisation (random-effects RR 0.90, 95% CI 0.70 to
1.15; participants = 1861; trials = 15; very low-certainty evidence) or on health-related quality of life up to three months, measured
with the European Quality of Life - 5 Dimensions - 3 Levels scale (MD -0.04 points, 95% CI -0.11 to 0.03; participants = 377; trial
= 1; low-certainty evidence). There was no evidence of effect on the occurrence of serious adverse events during treatment (random-
effects RR 1.05, 95% CI 0.85 to 1.29; participants = 1861; trials = 15; very low-certainty evidence), liver-related mortality up to three
months following randomisation (random-effects RR 0.89, 95% CI 0.69 to 1.14; participants = 1861; trials = 15; very low-certainty
evidence), number of participants with any complications up to three months following randomisation (random-effects RR 1.04, 95%
CI 0.86 to 1.27; participants = 1861; very low-certainty evidence), and number of participants of non-serious adverse events up to
three months’ follow-up after end of treatment (random-effects RR 1.99, 95% CI 0.72 to 5.48; participants = 160; trials = 4; very low-
certainty evidence). Based on the information that we collected from the published trial reports, only one of the trials seems not to be
industry-funded, and the remaining 15 trials did not report clearly whether they were partly or completely funded by the industry.
Authors’ conclusions
We are very uncertain about the effect estimate of no difference between glucocorticosteroids and placebo or no intervention on all-
cause mortality and serious adverse events during treatment because the certainty of evidence was very low, and low for health-related
quality of life. Due to inadequate reporting, we cannot exclude increases in adverse events. As the CIs were wide, we cannot rule
out significant benefits or harms of glucocorticosteroids. Therefore, we need placebo-controlled randomised clinical trials, designed
according to the SPIRIT guidelines and reported according to the CONSORT guidelines. Future trials ought to report depersonalised
individual participant data, so that proper individual participant data meta-analyses of the effects of glucocorticosteroids in subgroups
can be conducted.
P L A I N L A N G U A G E S U M M A R Y
Glucocorticosteroids for people with alcoholic hepatitis
Review question
To assess the benefits and harms of glucocorticosteroids administered at any route, dose, and duration versus placebo or no intervention
in people with alcoholic hepatitis in terms of death, health-related quality of life, and complications.
Background
Excessive alcoholic consumption may damage the liver, causing alcoholic hepatitis. The first stage of liver damage in alcoholic hepatitis
is usually reversible if people abstain from drinking, but the risk of the disease developing further and getting more complications
increases with resumed drinking. A heavy drinker is considered a person who consumes more than 30 g (for men) or more than 20 g
(for women) of alcohol per day. Only 10 to 35 people out of 100 heavy drinkers with evidence of excessive fat in the liver would most
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probably develop alcoholic hepatitis. With time, alcoholic hepatitis will cause liver fibrosis (scarring of the liver) or liver cirrhosis with
complications (bleeding, infections, liver cancer, etc.).
Glucocorticosteroids are considered to have anti-inflammatory effects (relieving pain, swelling (oedema), fever). They are administered
to people with alcoholic hepatitis in order to repair their liver injury. However, the benefits and harms of glucocorticosteroids are not
well studied in randomised clinical trials (studies where people are randomly put into one of two or more treatment groups), and
therefore, it is uncertain if they should be used in clinical practice for people with alcoholic liver disease.
Search date
The date of the last search was 18 January 2019.
Study characteristics
Sixteen randomised clinical trials compared glucocorticosteroids with placebo or no intervention in people with alcoholic hepatitis.
Fifteen trials provided data for analysis (927 participants received glucocorticosteroids and 934 participants received placebo or no
intervention). Glucocorticosteroids were administered orally or as an injection for a median of 28 days (range 3 days to 12 weeks). The
trial participants were between 25 and 70 years old, 65% were men, and had different stages of alcoholic liver disease. Trial participants
were followed up to the moment of discharge from the hospital, or until they died (a median of 63 days), or for at least one year. Not all
trials reported the follow-up of participants. The trials were conducted in France, India, the UK, and the USA. Two trials administered
pentoxifylline (a medicine used for diseases of the blood vessels) to both glucocorticosteroids and placebo intervention groups.
Funding
Based on the information that we collected from the published trial reports, only one of the trials seems not to be industry-funded,
and the remaining 15 trials did not report clearly whether they were partly or completely funded by the industry.
Reliability of the evidence
The overall reliability of the evidence was low for health-related quality of life and very low for death due to any cause up to three
months following entry in the trial; serious side effects during treatment; liver-related death up to three months following entry in the
trial; number of participants with any complications up to three months following entry in the trial, and number of participants non-
serious side effects up to three months’ follow-up after the end of treatment. All trials but one were at overall high risk of bias, which
means that there is possibility of drawing wrong conclusions, exaggerating benefits, or underestimating harms of glucocorticosteroids
because of the way the trials were conducted and analysed.
Key results
We could not determine whether glucocorticosteroids had a positive or negative effect on people with alcoholic liver disease. Despite
available data on outcomes which included mortality, health-related quality of life, and serious complications, we were unable to draw
firm conclusions mainly because available data were still insufficient to produce robust results, trials were small, and the included
participants differed in severity of disease. Therefore, we have very little confidence in our conclusions.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glucocorticosteroids for people with alcoholic hepatitis
Patient or population: part icipants with alcoholic hepat it is at high risk of mortality and morbidity
Settings: hospitals and clinics
Intervention: glucocort icosteroids
Comparison: placebo or no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no interven-
tion
Glucocorticosteroids
All- cause mortality: up
to 3 months’ follow-up
after randomisation
299 per 1000 278 per 1000
(210 to 344)
RR 0.90
(0.70 to 1.15)
1861
(15 RCTs)
⊕©©©
Very lowa
We downgraded for in-
consistency because of
select ion bias in the
trials: trials either in-
cluded or excluded peo-
ple with gastrointest i-
nal haemorrhage, ac-
t ive pept ic ulcer dis-
ease, pancreat it is, renal
failure, bacterial infec-
t ions
The OIS was 7870 par-
t icipants.
Health- related quality
of life: up to 3 months
(measured with Euro-
pean Quality of Life - 5
Dimensions - 3 Levels
(EQ-5D-3L)b scale)
The mean value was 0.
592
The mean value was 0.
553
(0.502 to 0.604)
MD -0.04 (-0.11 to 0.
03)
377
(1 RCT)
⊕⊕©©
Lowc
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Serious adverse events
during treatment
362 per 1000 381 per 1000
(398 to 467)
RR 1.05
(0.85 to
1.29)
1861
(15 RCTs)
⊕©©©
Very lowd
The OIS was 4197 par-
t icipants.
Liver- related mortal-
ity: up to 3 months’ fol-
low-up after randomi-
sation
299 per 1000 267 per 1000
(207 to 341)
RR 0.89
(0.69 to 1.14)
1861
(15 RCTs)
⊕©©©
Very lowe
The OIS was 7987 par-
t icipants.
Participants with any
complication: up to 3
months following ran-
domisation
444 per 1000 462 per 1000
(382 to 564)
RR 1.04
(0.86 to 1.27)
1861
(15 RCTs)
⊕©©©
Very lowf
The OIS was 5980 par-
t icipants.
Participants with non-
seri-
ous adverse events: up
to 3 months’ follow-up
after randomisation
52 per 1000 104 per 1000
(38 to 285)
RR 1.99
(0.72 to 5.48)
160
(4 RCTs)
⊕©©©
Very lowg
The OIS was 2698 par-
t icipants.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; MD: mean dif ference; OIS: opt imal information size; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group: certainty of evidence grades
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded three levels: one level due to within-study risk of bias (high overall risk of bias in all the trials but one (Thursz
2015); one level due to inconsistency of the data (there is wide variat ion in the ef fect est imates across studies; there is
lit t le overlap of conf idence intervals associated with the ef fect est imates; presence of moderate heterogeneity: I² = 45%;
heterogeneity could be explained with select ion bias); one level due to imprecision (the OIS was not reached).
bEQ-5D-5L: a self -report , mult iple-choice quest ionnaire that provides a simple descript ive prof ile and a single index value
for health status. The EQ-5D-5L essent ially consists of two pages: the EQ-5D descript ive system (on page 2) and the EQ
visual analogue scale (EQ VAS) (on page 3). The descript ive system comprises the following f ive dimensions: mobility, self -5
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care, usual act ivit ies, pain/ discomfort , and anxiety/ depression. Each dimension has f ive levels: no problems; slight problems;
moderate problems; severe problems; and extreme problems. The EQ VAS records the respondent ’s self -rated health on a
vert ical, visual analogue scale. A summary index with a maximum score of 1 can be derived f rom these f ive dimensions by
conversion with a table of scores. The maximum score of 1 indicates the best health state, by contrast with the scores of
individual quest ions, where higher scores indicate more severe or f requent problems. Utility values for perfect health and
death are 1 and 0, respect ively. In addit ion, there is a visual analogue scale to indicate the general health status with 100
indicat ing the best health status.
cDowngraded two levels: one level due to within-study risk of bias (high overall risk of bias in the trial); one level due to
imprecision of ef fect est imates (fewer than 400 part icipants).
dDowngraded three levels: one level due to within-study risk of bias (high overall risk of bias in all the trials but one); one level
due to inconsistency of the data (there was wide variat ion in the ef fect est imates across studies; there was lit t le overlap of
conf idence intervals associated with the ef fect est imates; presence of moderate heterogeneity: I² = 36%; heterogeneity could
be explained with select ion bias); one level due to imprecision (the OIS was not reached).
eDowngraded three levels: one level due to within-study risk of bias (high overall risk of bias in all the trials but one); one
level due to inconsistency of the data (there is wide variat ion in the ef fect est imates across studies; there is lit t le overlap of
conf idence intervals associated with the ef fect est imates; presence of moderate heterogeneity: I² = 46%; heterogeneity could
be explained with select ion bias); one level due to imprecision (the OIS was not reached).
fDowngraded three levels: one level due to within-study risk of bias (high overall risk of bias in all the trials but one); one level
due to inconsistency of the data (there was wide variat ion in the ef fect est imates across studies; there was lit t le overlap of
conf idence intervals associated with the ef fect est imates; presence of moderate heterogeneity: I² = 41%; heterogeneity could
be explained with select ion bias); one level due to imprecision (the OIS was not reached).
gDowngraded four levels: one level due to within-study risk of bias (high overall risk of bias in all the trials but one); one level
due to inconsistency of the data (there is lit t le overlap of conf idence intervals associated with the ef fect est imates); one level
due to publicat ion bias (only four trials with a small number of part icipants reported on non-serious adverse events); one level
due to imprecision (the OIS was not reached).
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B A C K G R O U N D
Description of the condition
The term ’alcoholic hepatitis’ was used for the first time in a paper
by Beckett and colleagues in 1961 (Beckett 1961), but clinical
jaundice after excessive ethanol consumption was reported in the
literature long before that, in 1912 (French 1912; Gerber 1973).
Most probably, these reports represented people with alcoholic
hepatitis (Mendenhall 1984; Jensen 1994).
Alcoholic hepatitis is a serious formof alcoholic liver disease (injury
of the liver due to excessive alcohol consumption) (WHO 2010).
The first stage of liver damage in alcoholic hepatitis is usually re-
versible if people abstain from drinking, but the risk of progres-
sion to fibrosis and cirrhosis increases with resumed drinking (Ellis
2012). The accumulation of fat in the hepatocytes causes disrup-
tion of the mitochondrial beta-oxidation of fatty acids, accumula-
tion of lipotoxic metabolites, and release of reactive oxygen species
(Lieber 1999; Wu 1999; Petrasek 2013). Lipotoxic metabolites
and reactive oxygen species lead to cell death and liver inflamma-
tion (Wu 1999; Petrasek 2013; WHO 2013). Alcoholic hepatitis
is a histological form of alcoholic liver disease, characterised by
steatosis (the earliest stage of alcoholic liver damage) and necroin-
flammation (EASL 2018). Alcoholic hepatitis can be resolved if
people abstain from drinking, but the risk of death will depend
on the severity of the liver damage and drinking patterns. In 20%
to 40% of persistent heavy drinkers (defined as alcohol consump-
tion per day of more than 30 g in men (EASL 2018) and more
than 20 g in women (EASL 2018), alcoholic hepatitis and other
complications may develop (WHO 2013).
Severe alcoholic hepatitis may be characterised by clinically clear
signs of jaundice, coagulopathy, liver decompensation with as-
cites, portal hypertension, variceal bleeding, hepatorenal syn-
drome, hepatic encephalopathy, systemic inflammatory response
syndrome, or sepsis (Becker 1996; EASL 2018). Typically, alco-
holic hepatitis presents in people aged between 40 and 50 years.
Among the risk factors of developing severe alcoholic hepatitis
are being female, Hispanic ethnicity, various types of alcohol,
binge drinking, poor nutrition, obesity, etc. (WHO 2010). Sev-
eral composite prognostic scores exist to distinguish people with
poor prognosis from those who can become abstinent, instituting
supportive care, until recovery is achieved. Some of these scores,
designed to predict mortality, areMaddrey’s discriminant function
(Maddrey 1978), the model of end-stage liver disease (MELD)
score (Dunn 2005); the Glasgow alcoholic hepatitis score (Forrest
2005); and the age, bilirubin, international normalised ratio, cre-
atinine (ABIC) score (Dominguez 2008).
The Maddrey Discriminant Function is the most often used score
in severe alcoholic hepatitis to identify people in potential need
of glucocorticosteroids (also known as glucocorticoids, corticos-
teroids, or steroids). The one-month survival of people with al-
coholic hepatitis and with Maddrey’s score higher than 32 varied
between 50% and 65% (Carithers 1989; Phillips 2006). The Lille
Model (www.lillemodel.com) is the only validated model so far
to assess glucocorticosteroid response and is highly predictive of
death at six months (P < 0.001) in people with severe alcoholic
hepatitis (Louvet 2007). A Lille Model score greater than 0.45,
calculated after seven days of treatment with prednisolone, means
failure to respond to treatment and predicts a six-month mortality
of about 75% (Lefkowitch 2005).
Description of the intervention
Glucocorticosteroids are used as anti-inflammatory drugs. Glu-
cocorticosteroid agents mimic the endogenously produced gluco-
corticoid (cortisol) (Rhen 2005). Glucocorticosteroids, primarily
regulated by corticotropin, are considered to have anti-inflamma-
tory effects as well as metabolic and immunogenic effects (Rhen
2005). It is agreed that the anti-inflammatory effects of gluco-
corticosteroids are mediated primarily through repression of gene
transcription (Schäcke 2002).
How the intervention might work
Glucocorticosteroids administered to people with alcoholic hep-
atitis repair the liver injury by decreasing the liver polymorphonu-
clear neutrophil (PMN) (effector cells) infiltrates and the level of
proinflammatory mediators such as tumour necrosis factor-alpha
(TNF-alpha), intercellular adhesion molecule 1, and interleukin
(IL)-6 and IL-8 in the liver tissue (Taïeb 2000; Spahr 2001). The
benefits of corticosteroids ensue from short-term vascular changes
(Schäcke 2002). However, adverse events have still been poorly
reported (Christensen 1995; Rambaldi 2008).
Why it is important to do this review
Several randomised clinical trials have studied the benefits and
harms of corticosteroids for people with alcoholic hepatitis to
determine the best route of administration, dose, and duration.
However, results have been contradictory. Some systematic reviews
(Christensen 1995; Rambaldi 2008), and meta-analyses of ran-
domised clinical trials (Reynolds 1989; Imperiale 1990; Daures
1991; Christensen 1999; Mathurin 2011; Louvet 2018), have
been published. The review authors explained their various con-
clusions regarding patient-orientated outcomes as being due to dif-
ferences in glucocorticosteroid regimens, trial quality, participants’
characteristics, and clinical spectrumof the disease. Reynolds 1989
concluded that corticosteroid treatment could help only the most
severely ill people with severe alcoholic hepatitis characterised
by high levels of serum bilirubin, prolonged prothrombin times,
and development of hepatic encephalopathy. Imperiale 1990 con-
cluded that glucocorticosteroids reduced short-term mortality in
people with severe alcoholic hepatitis, provided that they also had
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hepatic encephalopathy but did not have severe gastrointestinal
bleeding. Daures 1991 concluded that further randomised clinical
trials were needed to confirm the benefits and harms of glucocor-
ticosteroids, especially in people with severe alcoholic hepatitis.
Christensen 1995, Christensen 1999, and Rambaldi 2006 could
not find sufficient proof supporting the routine use of glucocorti-
costeroids in people with alcoholic hepatitis, including those with
hepatic encephalopathy. Rambaldi 2008 concluded that glucocor-
ticosteroids did not improve overall survival in people with alco-
holic hepatitis. Based on the Trial Sequential Analysis of the sub-
group of people withMaddrey’s score of at least 32 or spontaneous
hepatic encephalopathy, the required information size of 2420
people for the outcome mortality was far from reached, with only
249 participants randomised in the six trials (Rambaldi 2008).
Using the Lille Model, Mathurin 2011 concluded that glucocor-
ticosteroids significantly improved 28-day survival in people with
severe alcoholic hepatitis. Mathurin 2011 based the meta-analysis
on individual patient data from five selected randomised clinical
trials and was accordingly at risk of preferential selection. In 2018,
Louvet and colleagues published four meta-analyses in one publi-
cation in which they assessed the effects of corticosteroids versus
placebo or control, corticosteroids versus pentoxifylline, corticos-
teroids plus pentoxifylline versus corticosteroids plus placebo or
control, and pentoxifylline versus placebo in four meta-analyses
(Louvet 2018). The conclusions Louvet and colleagues made was
that corticosteroids reduced the risk of death within 28 days of
treatment, but not in the next six months. However, Louvet 2018
did not contain new references to randomised clinical trials of in-
terest to our review. The present review is an update of our previ-
ously published Cochrane systematic review, assessing the benefits
and harms of glucocorticosteroids in people with severe alcoholic
hepatitis with or without complications.
O B J E C T I V E S
To assess the benefits and harms of glucocorticosteroids in people
with alcoholic hepatitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised clinical trials in which glucocorticos-
teroids were assessed in people with alcoholic hepatitis, irrespec-
tive of year or language of publication or format.
We found no reports of harm in the quasi-randomised or observa-
tional studies retrieved with our searches for randomised clinical
trials (Excluded studies).
Types of participants
We included adults with alcoholic hepatitis, diagnosed according
to the diagnostic work-up used in the individual randomised clin-
ical trial. Alcoholic hepatitis could have been established through
clinical or biochemical diagnostic criteria, or both.
We considered alcoholic hepatitis as mild if a randomised partici-
pant had a Maddrey’s score less than 32 (Maddrey’s score = 4.6 ×
(prothrombin time - control time)(s) + serum bilirubin (mg per
dL)) (Maddrey 1978). Usually, people with mild alcoholic hepati-
tis do not have concomitant gastrointestinal bleeding.
We considered alcoholic hepatitis as severe at any stage of the al-
coholic liver disease with the presence of spontaneous hepatic en-
cephalopathy; or Maddrey’s score of 32 or higher. We also exam-
ined whether there was a difference in terms of initiation of treat-
ment with glucocorticosteroids in trials using the Maddrey’s score
where severe alcoholic hepatitis was defined as 32 or higher.
Included trial participants diagnosed with severe alcoholic hep-
atitis could also manifest with hepatic encephalopathy, gastroin-
testinal bleeding, cirrhosis (e.g. classified with Child-Pugh score -
Child-Pugh type C (Pugh 1973)), ascites, hepatorenal syndrome,
hyponatraemia, or spontaneous bacterial peritonitis.
For studies not reporting the Maddrey’s score, we used the classi-
fications for mild and severe alcoholic hepatitis as provided by the
trialists.
Types of interventions
Glucocorticosteroids administered by any route, dose, and dura-
tion versus placebo or no intervention.
We allowed cointerventions in the trial groups, provided theywere
the same.
Types of outcome measures
Primary outcomes
• All-cause mortality: up to three months’ follow-up after
randomisation (the primary time point for drawing our main
conclusion); at the end of treatment (post hoc analysis); and one
year following randomisation (post hoc analysis).
• Health-related quality of life as defined by the trial authors.
• Serious adverse events during treatment. We used the
International Conference on Harmonisation (ICH) Guidelines
for Good Clinical Practice’s definition of a serious adverse event
(ICH-GCP 1997), that is, any untoward medical occurrence
that resulted in death, was life threatening, required
hospitalisation or prolongation of existing hospitalisation,
resulted in persistent or significant disability or incapacity, or was
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a congenital anomaly or birth defect. We considered all other
adverse events as non-serious (see Secondary outcomes).
Secondary outcomes
• Liver-related mortality up to three months’ follow-up after
randomisation.
• Participants with any complication up to three months’
follow-up after randomisation (i.e. ascites, hepatorenal
syndrome, spontaneous bacterial peritonitis, gastrointestinal
bleeding, hepatic encephalopathy, non-obstructive jaundice,
systemic inflammatory response syndrome, sepsis, or
hepatocellular carcinoma, or a combination of any of these).
• Participants with non-serious adverse events up to three
months’ follow-up after randomisation.
Exploratory analysis
• Participants with an increase of liver enzymes as defined by
the trialists.
• Participants with a decrease of prothrombin index as
defined by the trialists.
• Participants with a decrease of serum albumin as defined by
the trialists.
Search methods for identification of studies
Electronic searches
We searchedCochrane Hepato-Biliary’s Controlled Trials Register
(Gluud 2017; 18 January 2019), Cochrane Central Register of
Controlled Trials (CENTRAL; 2019, Issue 1) in the Cochrane Li-
brary, MEDLINEOvid (1946 to 18 January 2019), Embase Ovid
(1974 to 18 January 2019), LILACS, and Science Citation In-
dex Expanded (Web of Science; 1900 to 18 January 2019) (Royle
2003). We applied no language or document-type restrictions.
Appendix 1 shows the search strategies with the time spans of the
searches.
Searching other resources
We searched online trials registries such as ClinicalTri-
als.gov ( clinicaltrials.gov), European Medicines Agency (EMA;
www.ema.europa.eu),WorldHealthOrganization (WHO) Inter-
national Clinical Trial Registry Platform ( www.who.int/ictrp), the
Food and Drug Administration (FDA; www.fda.gov), eLibrary,
and pharmaceutical company sources for ongoing or unpublished
trials (last search 29 January 2019).
We handsearched the reference lists of articles from the comput-
erised databases and relevant review articles.
Data collection and analysis
We followed the guidelines provided in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a), and the
Cochrane Hepato-Biliary Module (Gluud 2017). We performed
the analyses using ReviewManager 5 (ReviewManager 2014) and
Trial Sequential Analysis (Thorlund 2011; TSA 2011; Wetterslev
2017). We assessed the evidence according to Jakobsen and col-
leagues (Jakobsen 2014).
Selection of studies
We retrieved the full-text publications that we considered as poten-
tially eligible for inclusion after reading their titles and abstracts.
Three review authors (CP, DV, GC) independently reviewed the
full-text publications for eligibility. The review authors assessed
each publication to determine if trial participants and the inter-
ventions administered met the inclusion criteria. We included ab-
stracts if there were sufficient data for analysis. We resolved dis-
agreements by discussion or consulting any of the remaining re-
view authors for arbitration.
Data extraction and management
Three review authors (CP, DV, GC) independently completed a
data extraction form for all included trials, agreed on among the
authors in advance. Authors extracted general information on the
trial, such as publication title; place and year of publication; trial
design; inclusion and exclusion criteria; preliminary sample size
calculation reached or not; number of participants randomised in
each trial and following treatment allocation; diagnostic work-up;
age (mean or median); sex or sex ratio; race; coinfection; type,
dose, and route of administration of glucocorticosteroids and their
possible link with adverse events; concurrent medications used;
length of trial; and length of follow-up. Three review authors (CP,
DV, and GC) also extracted data on malnutrition whenever it was
clearly defined by the trial authors.
The review authors resolved disagreements by discussion or asking
the advice of the review arbitrator (CG).
Assessment of risk of bias in included studies
Three review authors (CP, DV, and GC) independently assessed
the risk of bias of each included trial according to the recommen-
dations in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011b), the Cochrane Hepato-Biliary Module
(Gluud 2017), and methodological studies (Schulz 1995; Moher
1998; Kjaergard 2001; Wood 2008; Savovi 2012a; Savovi
2012b; Lundh 2017). We used the following definitions in the
assessment of risk of bias.
Allocation sequence generation
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• Low risk of bias: the study performed sequence generation
using computer random number generation or a random
number table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice were adequate if an independent person not
otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random. We only included such studies for assessment of harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We only
included such studies for assessment of harms.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judged that the
outcome was not likely to have been influenced by lack of
blinding; or blinding of participants and key study personnel
ensured, and it was unlikely that the blinding could have been
broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk;’ or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome was likely to have been
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding.
Blinded outcome assessment
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judged that the
outcome measurement was not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk;’ or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to have been
influenced by lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to have induced bias on
the results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: all-cause mortality, serious adverse events, and liver-
related mortality. If the original trial protocol was available, the
outcomes were those called for in that protocol. If the trial
protocol was obtained from a trials registry (e.g.
www.clinicaltrials.gov), the outcomes sought should have been
those enumerated in the original protocol if the trial protocol
was registered before or at the time that the trial was begun. If
the trial protocol was registered after the trial was begun, those
outcomes were not considered reliable.
• Unclear risk of bias: not all predefined outcomes were
reported fully, or it was unclear whether data on these outcomes
were recorded or not.
• High risk of bias: one or more predefined outcomes were
not reported.
Other bias
• Low risk of bias: the trial appeared free of other factors that
could have put it at risk of bias.
• Unclear risk of bias: the trial may or may not have been free
of other factors that could have put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could have put it at risk of bias.
Overall risk of bias
We judged each trial as having a low, unclear, or high risk of bias
based on the definitions described above. We included a bias risk
assessment combining all domains and judged the trials to be at
low risk of bias if none of the trial domains was assessed at high
or unclear risk of bias. Moreover, we considered trials with one or
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more domains with unclear or high risk of bias as trials at overall
high risk of bias.
Measures of treatment effect
Dichotomous outcomes
We used risk ratio (RR) with 95% confidence interval (CI) and
Trial Sequential Analysis-adjusted CI for dichotomous outcomes.
Continuous outcomes
We used mean difference (MD) with 95%CI and Trial Sequential
Analysis-adjusted CI for health-related quality of life. We planned
to use the standardised mean difference (SMD) with 95% CI if
trials used different measures for health-related quality of life.
Unit of analysis issues
Trial participants as randomised per intervention group. In case
of multiple treatment groups, we considered only the trial group
to which glucocorticosteroids were administered versus the group
that received placebo or no intervention. If a trial consisted of
more than two groups (either parallel or factorial design), we com-
pared the participants from all the glucocorticosteroid groups ver-
sus all participants from the placebo group(s). Had we been able
to include a cross-over trial from which we could extract data for
analyses, we would have used the data from the first treatment
period of the cross-over trial.
Dealing with missing data
If dichotomous or continuous data were missing in a published
report, whenever possible, we contacted the original investigators
to request the missing data.
If trialists used intention-to-treat analysis to deal withmissingdata,
we used these data in our primary analysis. Otherwise, we used
the data that were available to us.
Dealing with missing data using sensitivity analysis
As some trials reported only per-protocol analysis results, we in-
cluded missing data by considering participants as treatment fail-
ures or treatment successes by imputing them according to the
following two scenarios:
• extreme-case analysis favouring the experimental
intervention (’best-worse’ case scenario): none of the participants
who dropped out from the experimental group experienced the
outcome, but all of the participants who dropped out from the
control group experienced the outcome; including all
randomised participants in the denominator;
• extreme-case analysis favouring the control (’worst-best’
case scenario): all participants who dropped out from the
experimental group, but none from the control group
experienced the outcome; including all randomised participants
in the denominator.
For continuous outcomes (e.g. health-related quality of life), we
planned to perform a ’best-worst’ case scenario analysis assuming
that all participants lost to follow-up in the experimental group
had an improved outcome (the group mean plus 1 standard devi-
ation (SD)); and all those with missing outcomes in the control
group had a worsened outcome (the group mean minus 1 SD)
(Jakobsen 2014). We also planned to perform ’worst-best’ case
scenario analysis assuming that all participants lost to follow-up
in the experimental group had a worsened outcome (the group
mean minus 1 SD); and all those with missing outcomes in the
control group had an improved outcome (the group mean plus 1
SD) (Jakobsen 2014).
We performed the two sensitivity scenario analyses only for our
primary outcomes.
Assessment of heterogeneity
We addressed the presence of heterogeneity in both clinical and
statistical ways.
To assess heterogeneity between the trials, we specifically examined
the degree of heterogeneity observed in the results using the I²
statistic (Higgins 2002). As thresholds for the interpretation of the
I² statistic could bemisleading, we used the following approximate
guide for interpretation of heterogeneity provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity*;
• 50% to 90%: may represent substantial heterogeneity*;
• 75% to 100%: considerable heterogeneity*.
*The importance of the observed value of the I² statistic depends
on the magnitude and direction of effects and the strength of
evidence for heterogeneity (e.g. P value from the Chi² test, or a
CI for I² statistic).
For the heterogeneity adjustment of the required information size
in the Trial Sequential Analysis, we used diversity (D²) because
the I² statistic used for this purpose underestimates the required
information size (Wetterslev 2009).
Depending on the number of eligible trials, we planned to add
covariates to a meta-regression model to adjust for heterogeneity.
Assessment of reporting biases
Wedrew funnel plots to assess reporting biases from the individual
trials by plotting the RR on a logarithmic scale against its standard
error (Egger 1997; Sterne 2011).
For dichotomous outcomes, we tested asymmetry using the Har-
bord test in cases where Tau² was less than 0.1 (Harbord 2006),
and we planned to use Rücker 2008 in cases where Tau² was more
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than 0.1. For continuous outcomes, we planned to use the regres-
sion asymmetry test (Egger 1997), and the adjusted rank correla-
tion (Begg 1994).
Data synthesis
Meta-analysis
Weperformed themeta-analyses using ReviewManager 5 (Review
Manager 2014), and according to the recommendations of the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011).
We presented the results of dichotomous outcomes of individual
trials as RR with 95% CI and the results of the continuous out-
comes as MDwith 95%CI and Trial Sequential Analysis-adjusted
CI. We applied both the fixed-effect model (DeMets 1987) and
the random-effects model (DerSimonian 1986) meta-analyses. If
there were statistically significant discrepancies in the results (e.g.
one giving a significant intervention effect and the other no sig-
nificant intervention effect), we reported the more conservative
point estimate of the two (Jakobsen 2014). The more conservative
point estimate is the estimate closest to zero effect. If the two point
estimates were equal, we used the estimate with the widest CI as
our main result of the two analyses. We considered a P value of
0.025 or less, two-tailed, as statistically significant if the required
information size was reached due to the three primary outcomes
(Jakobsen 2014). Due to us expanding the number of analyses
conducted, we post hoc made the alpha level even lower. We used
the eight-step procedure to assess if the thresholds for significance
were crossed (Jakobsen 2014). We presented heterogeneity using
the I² statistic (Higgins 2002). We presented the results of the
individual trials and meta-analyses in the form of forest plots.
Where data were only available from one trial (in our case con-
tinuous data on health-related quality of life), we used Student’s
t-test (Student 1908). We planned to use Fisher’s exact test for
dichotomous data in a single trial (Fisher 1922).
Trial Sequential Analysis
We applied Trial Sequential Analysis for both dichotomous and
continuous outcomes (Thorlund 2011; TSA 2011; Wetterslev
2017), as cumulative meta-analyses are at risk of producing ran-
dom errors due to sparse data and repetitive testing of the accumu-
lating data (Wetterslev 2008; Wetterslev 2017). To control ran-
dom errors, we calculated the diversity-adjusted required infor-
mation size (DARIS) (i.e. the number of participants needed in a
meta-analysis to detect or reject a certain intervention effect) (Brok
2008; Wetterslev 2008; Brok 2009; Thorlund 2009; Wetterslev
2009; Thorlund 2010).
In our meta-analysis, we based the DARIS for dichotomous out-
comes on the event proportion in the control group; assumption
of a plausible relative risk reduction of 20% of the risk observed
in the included trials; a risk of type I error of 1% due to more than
three outcomes, and as we decided to performpost hoc analyses on
mortality at end of treatment and at one year following randomisa-
tion; a risk of type II error of 20%; and the diversity of the included
trials in the meta-analysis. For health-related quality of life, we
planned to estimate DARIS using a minimal relevant difference of
10% of the mean response observed in the control group; the SD;
alpha of 1% (Jakobsen 2014); beta of 20%; and the diversity as
estimated from the trials in the meta-analysis (Wetterslev 2009).
However, we did not conduct Trial Sequential Analysis because
only one trial provided data on health-related quality of life. We
also calculated and reported the Trial Sequential Analysis-adjusted
CI (Thorlund 2011).
The underlying assumptionofTrial Sequential Analysis is that test-
ing for statistical significance may be performed each time a new
trial is added to themeta-analysis. We added the trials according to
the year of publication, and, if more than one trial was published
in a year, we added trials alphabetically according to the last name
of the first author. On the basis of the DARIS, we constructed
the trial sequential monitoring boundaries for benefit, harm, and
futility (Wetterslev 2008; Thorlund 2011). These boundaries de-
termine the statistical inference one may draw regarding the cu-
mulative meta-analysis that has not reached theDARIS; if the trial
sequential monitoring boundary for benefit or harm is crossed be-
fore the DARIS is reached, firm evidence may be established and
further trials may be superfluous. However, if the boundaries are
not crossed, it is most probably necessary to continue doing trials
in order to detect or reject a certain intervention effect. However,
if the cumulative Z-curve crosses the trial sequential monitoring
boundaries for futility, no more trials may be needed.
A more detailed description of Trial Sequential Analysis can be
found at www.ctu.dk/tsa/ (Thorlund 2011).
Subgroup analysis and investigation of heterogeneity
Whenever possible, we performed the following subgroup analyses
for all-cause mortality up to three months after randomisation.
• Trials at low risk of bias compared to trials at high risk of
bias.
• Trials without for-profit funding compared to trials at risk
of for-profit funding (Lundh 2017).
• Trials with people with mild alcoholic hepatitis compared
to trials with people with severe alcoholic hepatitis, following
Maddrey’s score lower than 32 or 32 or higher or presence of
hepatic encephalopathy; or as provided by the trialists.
• Trials with glucocorticosteroid dose 40 mg or less compared
to trials with glucocorticosteroid dose more than 40 mg.
• Trials with people with severe alcoholic hepatitis without
cirrhosis compared to trials with people with severe alcoholic
hepatitis with cirrhosis. If cirrhosis is classified by Child-Pugh
score, then we may be able to perform additional subgroup
analyses in order to adjust for the clinical spectrum of the disease.
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• Trials with people with severe alcoholic hepatitis without
hepatorenal syndrome compared to trials with people with severe
alcoholic hepatitis with hepatorenal syndrome.
• Trials with people with severe alcoholic hepatitis without
ascites compared to trials with people with severe alcoholic
hepatitis with ascites.
We did not perform any additional subgroup analyses to those
planned in advance.
Sensitivity analysis
We planned to undertake additional sensitivity analyses to those
specified under Dealing with missing data should we have con-
sidered it necessary (e.g. trials published as full-paper articles, ab-
stracts, and unpublished trials).
We compared our GRADE assessment of imprecision with that
of Trial Sequential Analysis.
’Summary of findings’ tables
We used GRADEpro GDT 2015 to create a ’Summary of find-
ings’ table for the following outcomes: all-cause mortality: up to
three months’ follow-up after randomisation; health-related qual-
ity of life up to three months; serious adverse events during treat-
ment; liver-related mortality up to three months’ follow-up after
randomisation; participants with any complication up to three
months’ follow-up after randomisation; and number of partici-
pants with non-serious adverse events up to three months’ follow-
up after randomisation. The GRADE approach appraises the cer-
tainty of a body of evidence based on the extent to which one can
be confident that an estimate of effect or association reflects the
item being assessed. The certainty of a body of evidence consid-
ers within-study risk of bias, indirectness of the evidence (pop-
ulation, intervention, control, outcomes), unexplained inconsis-
tency (heterogeneity) of results (including problems with sub-
group analyses); imprecision of results, and risk of publication
bias (Balshem 2011; Guyatt 2011a; Guyatt 2011b; Guyatt 2011c;
Guyatt 2011d; Guyatt 2011e; Guyatt 2011f; Guyatt 2011g;
Guyatt 2011h; Guyatt 2013a; Guyatt 2013b; Guyatt 2013c;
Mustafa 2013; Guyatt 2017).
We defined the levels of evidence as ’high,’ ’moderate,’ ’low,’ or
’very low.’ These grades are defined as follows.
• High certainty: we are very confident that the true effect
lies close to that of the estimate of the effect.
• Moderate certainty: we are moderately confident in the
effect estimate: the true effect is likely to be close to the estimate
of the effect, but there is a possibility that it is substantially
different.
• Low certainty: our confidence in the effect estimate is
limited: the true effect may be substantially different from the
estimate of the effect.
• Very low certainty: we have very little confidence in the
effect estimate: the true effect is likely to be substantially
different from the estimate of effect.
R E S U L T S
Description of studies
See: Characteristics of included studies; and Characteristics of
excluded studies tables.
Results of the search
We identified 1307 potentially relevant records through the elec-
tronic searches (Figure 1). Of these, 37 records that referred to
16 randomised clinical trials fulfilled our inclusion criteria. We
found two trials published in abstract form (Mendenhall 1977;
Richardet 1993), and 14 trials described as full-text paper arti-
cles (Helman 1971; Porter 1971; Campra 1973; Blitzer 1977;
Maddrey 1978; Shumaker 1978; Depew 1980; Theodossi 1982;
Mendenhall 1984; Bories 1987; Carithers 1989; Ramond 1992;
De 2014; Thursz 2015). Our searches retrieved some quasi-ran-
domised trials or observational studies that included administra-
tion of glucocorticosteroids to people with alcoholic hepatitis, but
the studies did not report data of interest to our review. We iden-
tified no additional references by handsearching the reference lists
of articles, retrieved through the computerised databases.
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Figure 1. Study flow diagram.
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We found one registered trial on clinicaltrials.gov comparing
methylprednisolone versus placebo in severe alcoholic hepatitis
(NCT03160651). However, the trial has not yet started recruit-
ment of participants.
Included studies
Sixteen randomised clinical trials fulfilled our inclusion crite-
ria (Helman 1971; Porter 1971; Campra 1973; Blitzer 1977;
Mendenhall 1977;Maddrey 1978; Shumaker 1978; Depew 1980;
Theodossi 1982; Mendenhall 1984; Bories 1987; Carithers 1989;
Ramond 1992; Richardet 1993; De 2014; Thursz 2015). Two
were three-armed trials (Mendenhall 1977; Mendenhall 1984),
one trial was a randomised trial with a two-by-two factorial design
(Thursz 2015), one trial was a cross-over trial (Richardet 1993),
and the remaining were parallel, two-group design trials. There
were 1884 participants randomised in all trials. Some participants
from Mendenhall 1977 (pilot trial or feasibility trial) continued
participation in Mendenhall 1984. Three trials were conducted
in France, one in India, two in the UK, and 10 in the USA
(Characteristics of included studies table). All the trials reported
the sex (65% of the participants were men) and age of the partic-
ipants (range 25 years to 70 years). Four trials excluded women
(Blitzer 1977; Mendenhall 1977; Mendenhall 1984; De 2014).
Eleven trials reported to have included participants at different
stages of alcoholic liver disease due to hepatitis, fibrosis, or cir-
rhosis (Helman 1971; Porter 1971; Campra 1973; Blitzer 1977;
Maddrey 1978; Depew 1980; Theodossi 1982;Mendenhall 1984;
Bories 1987; Ramond 1992; Thursz 2015).Most trials established
diagnosis primarily through liver biopsy. One trial included only
participants with liver cirrhosis in addition to alcoholic hepati-
tis (De 2014). The remaining trials did not provide information
on the stage of disease. All the trials included participants with
recent history of alcohol consumption, increase of serum biliru-
bin, liver enzymes, prolonged prothrombin time, and participants
without previous treatment with glucocorticosteroids within the
three months before the start of the trial. Ten trials performed liver
biopsy whenever possible (Helman 1971; Porter 1971; Campra
1973; Blitzer 1977;Maddrey 1978; Shumaker 1978;Depew1980;
Bories 1987; Ramond 1992; Thursz 2015); however, it was an
inclusion criterion in only one trial, performed at admission and
after treatment (Helman 1971).
Ten trials reported the period of trial enrolment (range of one year
to five years; median of three years) (Campra 1973; Blitzer 1977;
Mendenhall 1977; Maddrey 1978; Depew 1980; Mendenhall
1984; Bories 1987; Carithers 1989; De 2014; Thursz 2015).
The earliest trial began participant recruitment in 1966 (Campra
1973), and the most recently published trial began recruitment in
2011 and completed it in 2014 (Thursz 2015).
Three trials followed participants up to one year (Mendenhall
1984; De 2014; Thursz 2015). The remaining trials followed their
participants to the moment of discharge from the hospital or until
death occurred, with a median duration of follow-up of 63 days
(range 28 to 120).
We could extract data for analysis from all 16 trials but one
(Richardet 1993).We contactedRichardet and colleagues in 2006,
but received no reply. In the remaining 15 trials, 182 participants
had mild alcoholic hepatitis and 1679 had severe alcoholic hepati-
tis. The analyses of the 15 trials accounted for 927 participants ran-
domised to glucocorticosteroids, and 934 participants randomised
to placebo or no intervention.
Based on the information that we collected from the published
trial reports, three of the trials were not industry-funded (Porter
1971; Ramond 1992; Thursz 2015), and the remaining 13 trials
did not report clearly if they were partly or completely funded by
the industry.
Experimental interventions
Glucocorticosteroids (prednisolone or 6-methylprednisolone in
equivalent dose of prednisolone) were administered orally or par-
enterally at different dose regimens and different durations. Twelve
trials assessed oral glucocorticosteroids using prednisolone 40 mg
or greater (Helman 1971; Mendenhall 1977; Maddrey 1978;
Shumaker 1978; Depew 1980; Mendenhall 1984; Bories 1987;
Carithers 1989; Ramond 1992; Richardet 1993; De 2014; Thursz
2015). Three trials also allowed parenteral administration to par-
ticipants whowere not able to swallow (Shumaker 1978; Carithers
1989; Ramond 1992). Two trials assessed oral glucocorticosteroids
using prednisolone less than 40 mg (Campra 1973; Blitzer 1977),
and in one trial the initial therapy was parenteral and then it was
administered orally (Porter 1971). One trial used only parenteral
(intravenous) glucocorticosteroids (Theodossi 1982).
The median duration of glucocorticosteroid administration was
28 days with a range of three days (Theodossi 1982) to 11 weeks
(De 2014): one week (Richardet 1993), three weeks (Mendenhall
1977), four weeks (Ramond 1992; Thursz 2015), 26 days (Blitzer
1977), one month (Maddrey 1978; Mendenhall 1984; Bories
1987), five weeks (Shumaker 1978; Carithers 1989), six weeks
(Helman 1971; Campra 1973; Depew 1980), 45 days (Porter
1971). Ten trials tapered the dose of prednisolone until it was
stopped (Helman 1971; Porter 1971; Campra 1973; Blitzer 1977;
Mendenhall 1977; Shumaker 1978; Depew 1980; Mendenhall
1984; Carithers 1989; De 2014).
Control interventions
Twelve trials used placebos that were identical in appearance to
the glucocorticosteroid intervention (Helman 1971; Porter 1971;
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Blitzer 1977; Mendenhall 1977; Maddrey 1978; Shumaker 1978;
Depew 1980; Mendenhall 1984; Carithers 1989; Ramond 1992;
De 2014; Thursz 2015), and four trials used no intervention (
Campra 1973; Theodossi 1982; Bories 1987; Richardet 1993).
Cointerventions
Two trials administered pentoxifylline to both glucocorticosteroids
and placebo intervention groups (De 2014; Thursz 2015). There
seemed to be no interaction between the intervention effects of
pentoxifylline and glucocorticosteroids (De 2014; Thursz 2015).
Outcomes
The Characteristics of included studies tables details the outcomes
reported in the individual trials. Five trials reported on outcomes
with a follow-up period up to three months after randomisation
(Helman 1971; Mendenhall 1977; Bories 1987; De 2014; Thursz
2015). Twelve trials reported on outcomes at the end of treat-
ment or at the moment of discharge from the hospital (Helman
1971; Porter 1971; Campra 1973; Blitzer 1977; Maddrey 1978;
Shumaker 1978; Depew 1980; Theodossi 1982; Bories 1987;
Carithers 1989; Ramond 1992; Richardet 1993). Three trials ex-
ceeded the 12-month follow-up period (Mendenhall 1984; De
2014; Thursz 2015).
Only one trial reported health-related quality of life, using the
European Quality of Life - 5 dimensions (EQ-5D) score regis-
tered to Eudra CT 2009-013897-42 and ISRCTN 88782125 and
it was reported in all the groups at three months’ follow-up af-
ter randomisation, and at one year (Thursz 2015; see Notes in
Characteristics of included studies table).
None of the trials provided usable data for meta-analyses of our
exploratory outcomes.
For further details on trial characteristics, see Characteristics of
included studies table.
Excluded studies
We excluded 29 publications from the final assessment with the
reasons for their exclusion provided in the Characteristics of
excluded studies table.
Among the excluded studies were two trials that used a nutritional
intervention in the control group (Lesesne 1978; Cabré 2000).
Although nutritional intervention as an overall intervention does
not seem to influence all-cause mortality or serious adverse events
(Feinberg 2017), including the Cabré 2000 and Lesesne 1978
trials in our review would not have affected our results noticeably
because these trials were small and had very few events.
Risk of bias in included studies
Allocation
Random sequence generation
We assessed the random sequence generation as low risk of
bias in eight trials (Porter 1971; Campra 1973; Blitzer 1977;
Maddrey 1978; Carithers 1989; Ramond 1992; De 2014; Thursz
2015), and as unclear in the remaining trials (Helman 1971;
Mendenhall 1977; Shumaker 1978; Depew 1980; Theodossi
1982; Mendenhall 1984; Bories 1987; Richardet 1993).
Allocation concealment
We assessed allocation concealment as low risk of bias in ten
trials (Helman 1971; Porter 1971; Campra 1973; Blitzer 1977;
Shumaker 1978; Theodossi 1982; Mendenhall 1984; Carithers
1989; Ramond 1992; Thursz 2015), and as unclear in the remain-
ing trials (Mendenhall 1977; Maddrey 1978; Depew 1980; Bories
1987; Richardet 1993; De 2014).
Blinding
Three trials were at high risk of performance bias as they were
open-label trials, without blinding of participants or investigators
(Campra 1973; Theodossi 1982; Bories 1987), and one trial used
placebo, but there was no description of it and we judged the risk
of bias as unclear (Richardet 1993). Twelve trials were blinded, us-
ing identical placebo, and hence, at low risk of bias (Helman 1971;
Porter 1971; Blitzer 1977; Mendenhall 1977; Maddrey 1978;
Shumaker 1978; Depew 1980; Mendenhall 1984b: Carithers
1989; Ramond 1992; De 2014; Thursz 2015).
We assessed four trials at low risk of detection bias (Porter 1971;
Shumaker 1978; De 2014; Thursz 2015), one trial at high risk
of bias (Carithers 1989), and the remaining 11 trials as unclear
risk of detection bias (Helman 1971; Campra 1973; Blitzer 1977;
Mendenhall 1977;Maddrey 1978; Depew 1980; Theodossi 1982;
Mendenhall 1984; Bories 1987; Ramond 1992; Richardet 1993).
Incomplete outcome data
We classed four trials at high risk of attrition bias because they
did not account for participants with missing outcomes (Porter
1971; Blitzer 1977; Theodossi 1982; Thursz 2015 (the latter re-
garding one-year follow-up results)). Twelve trials were assessed as
having low risk of attrition bias (Helman 1971; Campra 1973;
Mendenhall 1977;Maddrey 1978; Shumaker 1978; Depew 1980;
Mendenhall 1984; Bories 1987; Carithers 1989; Ramond 1992;
De 2014; Thursz 2015 (the latter regarding follow-up to end of
treatment and up to three-month follow-up)). We judged one trial
at unclear risk of bias (Richardet 1993).
Selective reporting
There were three trials at high risk of bias (Helman 1971;
Mendenhall 1977; Mendenhall 1984), and one trial at unclear
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risk of bias (Richardet 1993). We found a registered protocol for
only one trial (Thursz 2015). The remaining 11 trials reported all-
cause mortality, serious adverse events, and liver-related mortality.
Thus, 12 trials were at low risk of selective reporting bias.
Other potential sources of bias
We identified no other biases in 15 of the included trials. One trial
was published as an abstract; we assessed this domain at unclear
risk of other potential source of bias (Richardet 1993).
Overall risk of bias
We judged all trials but one (Thursz 2015) at high risk of bias.
Figure 2 and Figure 3 show our assessment of risk of bias of the
published trial reports (Characteristics of included studies table).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias domain presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias domain for each
included study.
18Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Effects of interventions
See: Summary of findings for the main comparison
Glucocorticosteroids for people with alcoholic hepatitis
Primary outcomes
All-cause mortality
Up to three months following randomisation
In total, 258/927 (27.8%) participants in the glucocorticosteroid
group died versus 279/934 (29.9%) participants in the control
group. There was no evidence of effect of glucocorticosteroids
on all-cause mortality (random-effects RR 0.90, 95% CI 0.70
to 1.15; participants = 1861; trials = 15; I² = 45% (moderate
heterogeneity; Analysis 1.1).We rated the certainty of the evidence
as low (Summary of findings for the main comparison).
We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve did not cross the trial se-
quential monitoring boundaries for benefit or harm, nor enter the
trial sequential monitoring area for futility in order to include an
intervention effect of 20% relative risk reduction (Figure 4). The
Trial Sequential analysis-adjusted CI was 0.36 to 2.32.
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Figure 4. All-cause mortality up to three months after randomisation. Fifteen trials provided data. The diversity-
adjusted required information size (DARIS) was calculated based on all-cause mortality of 30% in the control
group; relative risk reduction (RRR) in the glucocorticosteroid group of 20%; type I error of 1%; and type II
error of 20% (80% power). Trial diversity was 62%. The required information size was 6734 participants. The
cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm
(red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge with
red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5%
equal to Z-scores of +1.96 and -1.96.
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Visual inspection of the funnel plot suggested publication bias or
small-trial bias on all-cause mortality, but when using theHarbord
2006 test, we found no evidence of bias (P = 0.31) (Figure 5).
Figure 5. Funnel plot of comparison 1. Glucocorticosteroids versus no intervention/placebo, outcome 1.1
all-cause mortality.
’Best-worst’ case scenario analysis
The ’best-worst’ case scenario analysis on mortality up to three
months after randomisation produced two different results. While
there was no evidence of effect of glucocorticosteroids with the
random-effects model (RR 0.82, 95% CI 0.64 to 1.05; I² = 47%),
there was evidence of beneficial effect with the fixed-effect model
(RR 0.74, 95% CI 0.65 to 0.84; participants = 1861; trials =
15; I² = 47%; Analysis 3.1). Heterogeneity in both analyses was
moderate.
’Worst-best’ case scenario analysis
The ’worst-best’ case scenario analysis on mortality up to three
months after randomisation produced two different results. While
there was no evidence of effect of glucocorticosteroids with the
random-effects model (RR 0.97, 95% CI 0.73 to 1.29; I² = 62%),
there was evidence of a harmful effect with the fixed-effect model
(RR 1.21, 95% CI 1.06 to 1.37; I² = 62%; Analysis 3.2).
Our Trial Sequential Analysis assessment of imprecision coincided
with assessment of imprecision with GRADE for all-cause mor-
tality: three-months following randomisation.
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At the end of treatment (post hoc analysis)
Treatment lasted for a median of 28 days (range 3 days to 12
weeks). In total, 162/907 (17%) participants in the glucocorti-
costeroid group died versus 202/917 (22%) participants in the
control group. There was no evidence of effect of glucocorticos-
teroids on all-cause mortality (random-effects RR 0.87, 95% CI
0.66 to 1.15; participants = 1824; trials = 14; I² = 42%; moderate
heterogeneity; Analysis 1.1.1). We rated the certainty of the evi-
dence as low (not presented in Summary of findings for the main
comparison).
We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve did not cross the trial se-
quential monitoring boundaries for benefit or harm, and did not
enter the trial sequential monitoring area for futility in order to
exclude an intervention effect of 20% RRR (Figure 6). The Trial
Sequential Analysis-adjusted CI was CI 0.29 to 2.68.
Figure 6. All-cause mortality at the end of treatment (median 28 days (range 3 days to 12 weeks) (post hoc analysis).
Fourteen trials provided data. The diversity-adjusted required information size (DARIS) was calculated based
on all-cause mortality of 22% in the control group; relative risk reduction (RRR) in the glucocorticosteroid
group of 20%; type I error of 1%; and type II error of 20% (80% power). Trial diversity was 59%. The required
information size was 9242 participants. The cumulative Z-curve (blue line) did not cross the trial sequential
monitoring boundaries for benefit or harm (red inward sloping lines) and did not enter the trial sequential
monitoring area for futility (inner-wedge with red outward sloping lines). The green dotted lines show the
conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.
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Visual inspection of the funnel plot suggested publication bias or
small-trial bias on all-cause mortality at the end of treatment, but
when using the Harbord 2006 test, we found no evidence of bias
(P = 0.84) (Figure 5).
A sensitivity analysis of full-text articles (RR 0.85, 95% CI 0.64
to 1.11; participants = 1795; studies = 13; I² = 41%) and abstract
(RR 2.83, 95% CI 0.61 to 13.06; participants = 29; studies = 1;
I² = 0%) did not affect the overall result of mortality at the end of
treatment (analysis not shown).
One year following randomisation (post hoc analysis)
Three of the included trials provided data on all-cause mortality
one year following randomisation (Mendenhall 1984; De 2014;
Thursz 2015). In total, 274/668 (41%) participants in the gluco-
corticosteroid group died versus 265/664 (40%) participants in
the control group. There was no evidence of effect of glucocorti-
costeroids on all-cause mortality (random-effects RR 1.03, 95%
CI 0.91 to 1.17; participants = 1343; trials = 3; I² = 0%; no hetero-
geneity among the trials; Analysis 1.1.3). We rated the certainty of
the evidence as moderate (not presented in Summary of findings
for the main comparison).
We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve entered the area of futility,
which excludes an intervention effect of 20%RRR (Figure 7). The
Trial Sequential analysis-adjusted CI was CI 0.85 to 1.25.
Figure 7. All-cause mortality up to 1 year (post hoc analysis). Three trials provided data. The diversity-adjusted
required information size (DARIS) was calculated based on mortality in the control group of 40%; relative risk
reduction (RRR) of 20% in the glucocorticosteroid group; type I error of 1%; and type II error of 20% (80%
power). Trial diversity was 0%. The required information size was 1695 participants. The cumulative Z-curve
(blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping
lines). The cumulative Z-curve crossed the inner-wedge futility line (red outward sloping lines). The green
dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.
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Subgroup analysis and investigation of heterogeneity: all-
cause mortality up to three months after randomisation
Trials at low risk of bias compared to trials at high risk of bias
Thursz 2015 was the only trial at low risk of bias. There was no
significant difference (P = 0.32) between the subgroups of trials
including one trial at low risk of bias (RR 1.03, 95% CI 0.84 to
1.26; participants = 1103; studies = 1; I² = 0%; Analysis 2.1.1;
P = ) and the remaining 14 trials at high risk of bias (RR 0.86,
95% CI 0.63 to 1.17; participants = 758; studies = 14; I² = 48%;
Analysis 2.1.2).
Trials without for-profit funding compared to trials at risk of
for-profit funding
Thursz 2015 was the only trial which seemed not to have received
industry funding. There was no significant difference (P = 0.32)
between the subgroups of trials including one trial at low risk of
bias ((RR1.03, 95%CI 0.84 to 1.26; participants = 1103; Analysis
2.1.1) and the remaining 14 trials at high risk of bias ((RR 0.86,
95% CI 0.63 to 1.17; participants = 758; studies = 14; I² = 48%;
Analysis 2.1.2).
Trials with people with mild alcoholic hepatitis compared to
trials with severe alcoholic hepatitis, following Maddrey’s
score lower than 32 or 32 or higher or presence of hepatic
encephalopathy; or as provided by the trialists
There was no significant difference (P = 0.75) between the sub-
groups (mild alcoholic hepatitis: RR 1.02, 95% CI 0.58 to 1.80;
participants = 182; trials = 4; I² = 0%; Analysis 2.3.1) and severe
alcoholic hepatitis (RR 0.92, 95% CI 0.73 to 1.16; participants =
1679; trials = 14; I² = 37%; Analysis 2.3.2).
Trials with glucocorticosteroid dose 40 mg or less compared
to trials with glucocorticosteroid dose more than 40 mg
There was no significant difference (P = 0.22) between the sub-
groups of the trials with glucocorticosteroid dose less than or equal
to 40 mg (RR 0.75, 95% CI 0.50 to 1.14; participants = 1547;
trials = 10; I² = 58%; Analysis 2.4.1) and trials with glucocorti-
costeroid dose more than 40 mg (RR 1.02, 95% CI 0.79 to 1.30;
participants = 314; trials = 5; I² = 0%; Analysis 2.4.2).
Trials with people with severe alcoholic hepatitis without
cirrhosis compared to trials with people with severe alcoholic
hepatitis with cirrhosis
There was no significant difference (P = 0.83) between the sub-
groups of the trials with severe alcoholic hepatitis without cirrho-
sis (RR 0.79, 95% CI 0.18 to 3.48; participants = 123; trials =
3; I² = 77%; Analysis 2.5.1) and trials with people with severe
alcoholic hepatitis with cirrhosis (RR 0.92, 95% CI 0.74 to 1.16;
participants = 1738; studies = 12; I² = 35%; Analysis 2.5.2).
As only two trials classified cirrhosis by Child-Pugh score (Bories
1987; De 2014), and we did not know what classification system
the remaining trials had used, we could not perform a subgroup
analysis in order to adjust for the clinical spectrum of the disease.
Trials with people with severe alcoholic hepatitis without
hepatorenal syndrome compared to trials with people with
severe alcoholic hepatitis with hepatorenal syndrome
There was no significant difference (P = 0.64) between the sub-
groups of the trials with people with severe alcoholic hepatitis
without hepatorenal syndrome (RR 1.00, 95% CI 0.85 to 1.17;
participants = 1382; studies = 8; I² = 0%; Analysis 2.6.1) com-
pared to trials with people with severe alcoholic hepatitis with
hepatorenal syndrome (RR 0.56, 95% CI 0.05 to 6.49; partic-
ipants = 129; studies = 2; I² = 88%; Analysis 2.6.2). Five tri-
als did not clearly describe the presence of hepatorenal syndrome
(Blitzer 1977; Mendenhall 1977; Mendenhall 1984; Bories 1987;
Ramond 1992).
Trials with people with severe alcoholic hepatitis without
ascites compared to trials with people with severe alcoholic
hepatitis with ascites
As we did not have data on trials with participants not having
ascites, we could analyse only the subgroup of trials including par-
ticipants with ascites (RR 0.82, 95% CI 0.60 to 1.12; participants
= 729; trials = 13; I² = 48%; Analysis 2.7.1). In addition, two trials
did not clearly describe the presence of ascites (Mendenhall 1977;
Thursz 2015).
Health-related quality of life
Up to three months
Only one trial reported quality of life at a follow-up period of up
to three months, using responses to the EuropeanQuality of Life -
5 Dimensions - 3 Levels (EQ-5D-3L) (Thursz 2015). We applied
the Student’s t-test for the glucocorticosteroids versus the placebo
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group. We observed no difference between the two groups (MD
-0.04 points, 95% CI -0.11 to 0.03; Analysis 1.2). We rated the
certainty of the evidence as low (Summary of findings for themain
comparison). We did not perform Trial Sequential Analysis.
Up to one year
Only one trial reported quality of life at a follow-up period of up
to one year, using responses to the EQ-5D-3L (Thursz 2015). We
applied the Student’s t-test for the glucocorticosteroids versus the
placebo group.We observed no difference between the two groups
(MD 0.00 points; 95% CI -0.11 to 0.10; Analysis 1.2). We rated
the certainty of the evidence as low (not presented in Summary
of findings for the main comparison). We did not perform Trial
Sequential Analysis.
As the data for health-related quality of life came from one and
the same trial, we could not perform sensitivity analyses.
Serious adverse events during treatment
Fifteen trials reported number of participants with serious adverse
events during treatment. In total, 361/927 (38%) participants in
the glucocorticosteroid group had serious adverse events during
treatment versus 338/934 (36%) participants in the control group.
There was no evidence of effect of glucocorticosteroids on the oc-
currence of serious adverse events (random-effects RR 1.05, 95%
CI 0.85 to 1.29; participants = 1861; trials = 15; I² = 36%; moder-
ate heterogeneity; Analysis 1.3). We rated the certainty of the evi-
dence as very low (Summary of findings for themain comparison).
We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve entered the area of futility
which excludes an intervention effect of 20%RRR (Figure 8). The
Trial Sequential analysis-adjusted CI was 0.60 to 1.82.
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Figure 8. Serious adverse events during treatment. There are 15 trials providing data. The diversity-adjusted
required information size (DARIS) was calculated based on an incidence rate of serious adverse events in the
control group of 36%; relative risk reduction (RRR) of 20% in the glucocorticosteroid group; type I error of 1%;
and type II error of 20% (80% power). Trial diversity was 70%. The required information size was 6566
participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for
benefit or harm (red inward sloping lines), but it entered the trial sequential monitoring area for futility (inner-
wedge futility line red outward sloping lines) indicating that sufficient information was provided. The green
dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.
Table 1 shows the number of participants with the most often
occurring serious adverse events in 14 included trials; mortality
was not included. Table 2 presents themost often occurring serious
adverse events in Thursz 2015 because this trial did not specify the
individual number of participants with a serious adverse event.
We constructed a funnel plot for publication bias, and using the
Harbord 2006 test, we found no evidence of reporting bias (P =
0.63).
’Best-worst’ case scenario analysis
There was no evidence of effect of glucocorticosteroids on serious
adverse events during treatment, with neither of the models (ran-
dom-effects model: RR 1.00, 95% CI 0.83 to 1.21; participants =
1861; studies = 15; I² = 28%; not important heterogeneity; fixed-
effect model: RR 0.99, 95% CI 0.89 to 1.11; participants = 1861;
I² = 28%; not important heterogeneity; Analysis 4.1).
’Worst-best’ case scenario analysis
While there was evidence of a harmful effect of glucocorticos-
teroids with the fixed-effect model (RR 1.18, 95% CI 1.05 to
1.31; participants = 1861; I² = 38%), there was no evidence of
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effect of glucocorticosteroids with the random-effects model (RR
1.11, 95% CI 0.91 to 1.36; I² = 38%; Analysis 4.2).
Our Trial Sequential Analysis assessment of imprecision coincided
with assessment of imprecision with GRADE for serious adverse
events during treatment.
A sensitivity analysis of full-text articles (RR 1.03, 95% CI 0.84
to 1.27; participants = 1832; studies = 14; I² = 36%) and abstract
(RR 2.83, 95% CI 0.61 to 13.06; participants = 29; studies = 1; I²
= 0%) did not affect the serious adverse events during treatment
(analysis not shown).
Secondary outcomes
Liver-related mortality up to three months’ follow-up after
randomisation
In total, 257/927 (27.7%) participants in the glucocorticosteroid
group died versus 279/934 (29.9%) participants in the control
group. There was no evidence of effect of glucocorticosteroids
on liver-related mortality (random-effects RR 0.89, 95% CI 0.69
to 1.14; participants = 1861; trials = 15; I² = 46%; moderate
heterogeneity; Analysis 1.4).We rated the certainty of the evidence
as very low (Summary of findings for the main comparison).
We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve did not cross the trial se-
quential monitoring boundaries for benefit or harm, nor enter the
trial sequential monitoring area for futility in order to include an
intervention effect of 20% RRR (Figure 9). The Trial Sequential
analysis-adjusted CI was 0.32 to 2.45.
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Figure 9. Liver-related mortality up to three months after randomisation. Fifteen trials provided data. The
diversity-adjusted required information size (DARIS) was calculated based on liver-related mortality of 30% in
the control group; relative risk reduction (RRR) in the glucocorticosteroid group of 20%; type I error of 1%; and
type II error of 20% (80% power). Trial diversity was 68%. The required information size was 8059 participants.
The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or
harm (red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge
with red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of
5% equal to Z-scores of +1.96 and -1.96.
Our Trial Sequential Analysis assessment of imprecision coincided
with assessment of imprecisionwithGRADE for liver-relatedmor-
tality up to three months following randomisation.
Participants with any complication up to three months’
follow-up after randomisation
In total, 440/927 (47%) participants in the glucocorticosteroid
group had one or more complications versus 414/934 (44%) par-
ticipants in the control group. There was no evidence of effect
of glucocorticosteroids on the number of participants with any
complications (random-effects RR 1.04, 95% CI 0.86 to 1.27;
participants = 1861; I² = 42%; moderate heterogeneity; Analysis
1.5).We rated the certainty of the evidence as very low,mainly due
to within-study bias, inconsistency, and imprecision (Summary of
findings for the main comparison).
We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve did not cross the trial se-
quential monitoring boundaries for benefit or harm but it crossed
the trial sequential monitoring area for futility in order to include
an intervention effect of 20% RRR (Figure 10). The Trial Sequen-
tial analysis-adjusted CI was 0.67 to 1.63.
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Figure 10. Any complications up to three months’ follow-up after randomisation. Fifteen trials provided data. The
diversity-adjusted required information size (DARIS) was calculated based on any complications of 44% in the
control group; relative risk reduction (RRR) in the glucocorticosteroid group of 20%; type I error of 1%; and
type II error of 20% (80% power). Trial diversity was 75%. The required information size was 5887 participants.
The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or
harm (red inward sloping lines). The cumulative Z-curve crossed the inner-wedge futility line (red outward
sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-
scores of +1.96 and -1.96.
Our Trial Sequential Analysis assessment of imprecision coincided
with assessment of imprecision with GRADE for number of par-
ticipants with any complication up to three months’ follow-up
after randomisation.
Participants with non-serious adverse events up to three
months’ follow-up after randomisation
Only four trials reported non-serious adverse events such as
Cushingoid symptoms, vertigo, and fungal lesions. There was no
evidence of effect of glucocorticosteroids on number of partici-
pants with non-serious adverse events (random-effects RR 1.99,
95% CI 0.72 to 5.48; participants = 160; trials = 4; I² = 0%; no
heterogeneity; Analysis 1.6).We rated the certainty of the evidence
as very low to low (Summary of findings for themain comparison).
We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve did not cross the trial se-
quential monitoring boundaries for benefit or harm, nor did it
enter the trial sequential monitoring area for futility in order to
include an intervention effect of 50% RRR (Figure 11). The Trial
Sequential Analysis-adjusted CI was 0.01 to 249.60.
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Figure 11. Non-serious adverse events up to three months after randomisation. Four trials provided data. The
diversity-adjusted required information size (DARIS) was calculated based on non-serious adverse events of 5%
in the control group; relative risk reduction (RRR) in the glucocorticosteroid group of 50%; type I error of 1%;
and type II error of 20% (80% power). Trial diversity was 0%. The required information size was 2698
participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for
benefit or harm (red inward sloping lines) and did not enter the trial sequential monitoring area for futility
(inner-wedge with red outward sloping lines). The green dotted lines show the conventional boundaries of the
naive alpha of 5% equal to Z-scores of +1.96 and -1.96.
Our Trial Sequential Analysis assessment of imprecision coincided
with assessment of imprecision with GRADE for number of peo-
ple with non-serious adverse events up to three months following
randomisation.
Exploratory outcomes at the end of treatment
No trial reported on number of participants with change of level
of liver enzymes, prothrombin index, or serum albumin at the
end of treatment. This is why we could not perform the planned
exploratory analyses. Instead, post hoc, we decided to present in
a tabular way the extracted information on level of liver enzymes
reported in the trials by Campra 1973; Maddrey 1978; Theodossi
1982; and Carithers 1989 (Appendix 2); prothrombin index or
international normalised ratio reported in the trials by Campra
1973; Maddrey 1978; Theodossi 1982; Carithers 1989; Ramond
1992 (Appendix 3); and level of serum albumin (and bilirubin
post hoc) reported in the trials by Campra 1973; Maddrey 1978;
Depew1980;Theodossi 1982;Carithers 1989; andRamond 1992
(Appendix 4; Appendix 5).
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’Summary of findings’ table
We presented the key results on the outcomes all-cause mortality,
health-related quality of life, serious adverse events, liver-related
mortality, all complications, and non-serious adverse events in
Summary of findings for the main comparison. We assessed the
evidence as being very low for all listed outcomes but health-related
quality of life for which the evidence was low. We downgraded the
evidence because of within-study risk of bias, inconsistency of the
data, imprecision, and publication bias. We presented the results
obtained at predefined primary time points.
D I S C U S S I O N
Summary of main results
We included 16 randomised clinical trials comparing glucocorti-
costeroids versus placebo or no intervention in people with alco-
holic hepatitis. Fifteen trials provided data for analyses. Our meta-
analyses showed no beneficial or detrimental effects of glucocorti-
costeroids on any of our outcomes. In general, serious and non-se-
rious adverse events as well as complications were poorly reported
or the information was unclear, and hence, these analyses may be
subject to outcome reporting bias (Ioannidis 2009). Trial Sequen-
tial Analyses showed similar results. Based onmethodological con-
cerns, we classified the certainty of the evidence as low for health-
related quality of life, and very low for all the remaining primary
and secondary outcomes. We assessed the certainty of evidence
for all-cause mortality at one-year follow-up (post hoc analysis) as
moderate. As only one trial was at low risk of bias, it is more likely
that that the trials at high risk of bias were overestimating benefits
and overlooking harms.
Overall completeness and applicability of
evidence
The trial participants varied according to severity of alcoholic hep-
atitis and the trials were published between 1971 and 2015. How-
ever, only 1861 participants were included. During this time pe-
riod, glucocorticosteroid interventions varied regarding dose and
duration. The small number of trials and trial participants, with
the exception of Thursz 2015, the poor trial design and reporting,
all make the results of our review inconclusive. The high risk of
bias of almost all trials undermined the precision of our meta-
analyses results.
We were unable to assess if ethnicity had any influence on our
results, as data were either lacking or insufficient. The same ap-
plied for the nutritional status of the participants, as only one
trial reported on it (Mendenhall 1984). Mathurin and cowork-
ers proposed that people with alcoholic hepatitis with Maddrey’s
score of at least 32 should likely benefit from glucocorticosteroids
(Mathurin 2011). However, we found no significant effect of glu-
cocorticosteroids in this subgroup of trial participants.
This review is applicable to people with alcoholic hepatitis at dif-
ferent stages of the disease. Our meta-analyses and Trial Sequen-
tial Analyses seem to provide no evidence of benefit of glucocorti-
costeroids on all-cause mortality at one-year follow-up after ran-
domisation. It is also unlikely that glucocorticosteroids may have
a beneficial effect on mortality at the end of treatment and three
months following randomisation; however, due to mainly impre-
cision (the CI crossed the clinical decision threshold between rec-
ommending and not recommending treatment and the required
number of participants was far from reached), we could not ex-
clude the possibility of a short-term beneficial or harmful effect.
We could not say if glucocorticosteroids may have influenced in-
fection and gastrointestinal bleeding as we had no data for meta-
analysis. However, Thursz and colleagues’ analysis showed an in-
crease in the number of these complications in treated participants
(Thursz 2015). The only worst-best sensitivity analysis for all-
cause mortality and serious adverse events showed a tendency of
harmful effect of glucocorticosteroids compared to the best-worse
sensitivity analysis showing no difference in effect.
Quality of the evidence
The certainty of the evidence reflects only the quality of the in-
cluded trials, and this is why we could not be certain in our con-
clusions. We judged the overall certainty of evidence as low for
health-related quality of life to very low for all outcomes except for
all-cause mortality at one year after randomisation, for which the
certainty of the evidence wasmoderate (not presented in Summary
of findings for the main comparison). The randomisation proce-
dures were insufficiently reported in 15 of the trials. In addition
to downgrading the trials for within-study risk of bias, we also
downgraded the trials for imprecision of effect estimates due to the
number of participants included in the trials (all but one of the 14
trials had fewer than 400 participants), and for inconsistency of
the results (there was wide variation in the effect estimates across
the trials; there was little overlap of CIs associated with the effect
estimates; and we assessed heterogeneity of the data as moderate
with I² statistics of 36% to 46%, which could be explained with
selection bias). We found no statistical evidence of publication
bias or small-study bias.
In spite of the certainty of the evidence being very low or low,
we are reasonably confident in our recommendations regarding
implications for practice and for research. This ensues from our
analysis results and is based on the knowledge that trials at high risk
of bias overestimate benefits and underestimate harms. Therefore,
we found no supporting evidence for using glucocorticosteroids
in clinical practice. There is definitely a need for more transparent
reporting of individual participant data (NTAWG2015; Garattini
2016).
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Potential biases in the review process
The strengths of our review are that we have conducted our re-
view following the recommendations of Cochrane Hepato-Biliary
and the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011c;Gluud 2017).We included only randomised clin-
ical trials in our review. This creates a bias towards focusing on
benefits as short-term randomised trials often overlook harms.We
attempted to minimise possible selection biases by using a com-
prehensive search strategy. We combined searches in electronic
databases with extensive manual searches. In addition, we also
searched conference proceedings and abstract books, irrespective
of language. We think it is unlikely that we have missed any pub-
lished trials, but we cannot exclude the possibility that we have
missed unpublished trials. Visual inspection of the funnel plots
suggests publication bias or small-study bias on all-cause mortality
at the end of treatment and following three months after randomi-
sation in contrast to the statistical result with Harbord 2006 test
(Figure 5). We wrote to pharmaceutical companies and regulatory
authorities. We made extensive attempts to avoid risk of system
and random errors. We assessed the evidence with GRADE ap-
proach.
Limitations of our review were the small number of trials and the
small total number of participants. Having in mind that hepatitis
C viral disease was discovered as late as 1989, we might have run
the risk that the included trials initiated before 1989 did not in-
clude participants with only alcoholic hepatitis (Houghton 2009).
Furthermore, our results were hampered by the quality of the in-
cluded trials as well as imprecision and severe inconsistency. Even
though all trials provided data on mortality, data on other seri-
ous adverse events and complications were rarely reported, which
calls into question the reliability of the two latter analyses. Only
one trial reported quality of life. Moreover, by including primarily
randomised clinical trials we have focused on potential beneficial
effects and overlooked themany known harms connected with the
administration of glucocorticosteroids. Again, these flaws in our
review make us suspect that benefits are overestimated and harms
are underestimated.
When conducting our Trial Sequential Analyses, we used plausible
parameters to calculate our required information sizes. However,
we only used 80% power (beta = 20%). Had we used 90% power
(beta = 10%) or less, which is relevant in meta-analyses where
one does not want to discharge a potentially relevant intervention,
then we would have obtained larger required information sizes
and wider Trial Sequential Analyses-adjusted CIs (Garattini 2016;
Castellini 2017). Accordingly, the imprecision may be worse than
signalled by our analyses.
Agreements and disagreements with other
studies or reviews
The meta-analysis by Christensen 1995 found no effect of gluco-
corticosteroids versus placebo on mortality. The review included
data from 13 trials with 659 participants randomised. Rambaldi
2008 updated the meta-analysis by Christensen 1995, adding two
more trials with 62 participants randomised. Hence, Rambaldi
2008 concluded that depending on the estimation of the informa-
tion size, their review lacked another 1000 to 2000 participants
randomised to glucocorticosteroids versus placebo in order to be
able to either demonstrate or reject a clinically relevant 20% mor-
tality reduction.
Our review published in 2017 (Pavlov 2017) included two new
trials (De 2014; Thursz 2015), compared with the previous review
version published in a paper journal (Rambaldi 2008). The review
by Pavlov 2017 excluded two of the trials from the Rambaldi 2008
as they assessed glucocorticosteroids versus nutrition (Lesesne
1978; Cabré 2000). In addition, two trial reports turned out to be
the same trial (Shumaker 1978; Galambos 1984), and thus, they
are counted as one trial (Pavlov 2017). We did not identify any
new trials for the update of this current review.
Our systematic review of pair-wise comparison randomised clini-
cal trials is in agreement with the meta-analysis by Buzzetti 2017.
In this network meta-analysis, the authors found no significant
effects of glucocorticosteroids on mortality at maximal follow-up
and up to 90 days of follow-up.
Our review now includes 1861 participants. The Thursz 2015
trial included 1103 participants and found “a reduction in the 28-
day mortality in the prednisolone-treated group on logistic regres-
sion model analysis, but there was not clear evidence of benefit,
sustained beyond this point.” Mathurin 2011 performed “analy-
sis of individual data from five randomised clinical trials which
showed that corticosteroids significantly improved 28-day survival
in patients with severe alcoholic hepatitis.” In our present aggre-
gate meta-analysis, based on the certainty of evidence, we could
not determine whether there was an effect or not of glucocorticos-
teroids on mortality at ’end of treatment,’ which is quite close to
28 days. The review by Louvet 2018 (see Why it is important to
do this review section), assessed the effects of corticosteroids versus
placebo or control, corticosteroids versus pentoxifylline, corticos-
teroids plus pentoxifylline versus corticosteroids plus placebo or
control, and pentoxifylline versus placebo in four meta-analyses.
However, the number of participants with severe alcoholic hepati-
tis providing individual participants’ data from the six included in
the meta-analysis trials, comparing corticosteroids versus placebo
or control, was too small to draw afirmconclusionon the beneficial
or harmful effects of glucocorticosteroids. In addition, the control
intervention of two of the included six studies was nutrition or
antioxidants, which did not compare well with the placebo group
of participants. The conclusions Louvet and colleagues made was
that “corticosteroids used to reduce risk of death within 28 days
of treatment, but not in the following six months. This loss of
efficacy over time indicates a need for new therapeutic strategies to
improve medium-term outcomes.” Louvet and colleagues did not
assess the risk of bias and the quality of the included trials which
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adds further to the unreliability of their conclusions.
Clinical guidelines recommend prescribing glucocorticosteroids as
follows: AASLD 2010 reads: “Patients with severe disease (Mad-
drey’s Discriminant Function (MDF) score of ≥ 32, with or
without hepatic encephalopathy) and lacking contraindications to
steroid use should be considered for a four-week course of pred-
nisolone (40 mg/day for 28 days, typically followed by discontin-
uation or a 2-week taper) (Class I, level A)” and EASL 2012 reads:
“First-line therapy in patients with severe alcoholic hepatitis in-
cludes corticosteroids or, in case of ongoing sepsis, pentoxifylline
(Recommendation B1).” In the absence of active infection, EASL
2018 suggests the use of corticosteroids (prednisolone 40 mg/day
or methylprednisolone 32 mg/day) for people with severe alco-
holic hepatitis to reduce short-term mortality (Grade A1). How-
ever, in our present meta-analysis, we could not rule out a benefi-
cial or harmful effect of glucocorticosteroids in people with severe
alcoholic hepatitis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We are very uncertain about the effect estimate of no difference
between glucocorticosteroids and placebo or no intervention on
all-cause mortality and serious adverse events during treatment
because the risk of bias was high and the certainty of the evidence
was very low. Our confidence in the effect of glucocorticosteroids
on health-related quality of life is low. Due to inadequate report-
ing, we cannot exclude increases in adverse events. As the confi-
dence intervals, except for one-year all-cause mortality, were wide,
we cannot rule out significant benefits or harms of glucocorticos-
teroids.
Implications for research
As there could be some people with alcoholic hepatitis who could
benefit from glucocorticosteroids, it could be of use for researchers
to study further the effects of glucocorticosteroids in randomised
clinical trials on short-term all-cause mortality. Additional evi-
dence evaluating the effect on health-related quality of life is also
needed. Future trials ought to be designed according to the SPIRIT
guidelines ( www.spirit-statement.org/) and reported according to
the CONSORT guidelines ( www.consort-statement.org). Future
trials ought to report individual participant data, so that proper
individual participant data meta-analyses of the effects of gluco-
corticosteroids in subgroups can be conducted (NTAWG 2015;
Garattini 2016).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Blitzer 1977
Methods Prospective, double-blind randomised trial
Country: USA
Dates: 1971-1973
Intention-to-treat analysis: no
Sample size calculation: not reported
Participants Demographic characteristics
Age (mean): prednisolone group: 47.2 years; control group: 48.4 years
Sex: 100% men
Inclusion criteria and degree of severity
People with alcoholic hepatitis meeting the following criteria after ≥ 5 days in hospital:
recent history of heavy alcohol consumption (> 1 pint whiskey per day or alcoholic
equivalent); hepatomegaly based on physical examination (palpable > 5 cm below the
costal margin) or liver scan or both; total serum bilirubin > 5 mg/100 mL; and ≥ 2
abnormalities of AST > 100 Reitman-Frankel units/mL, serum albumin concentration
< 3 g/100 mL, or prothrombin time > 2 s greater than control value
Liver biopsies: performed whenever possible, but were not required for admission to the
study. 14 biopsies proved alcoholic hepatitis
Neither positive PPD skin tests nor active tuberculosis excluded people from randomisa-
tion. No positive PPD skin tests, and 1 active tuberculosis continued to receive isoniazid
and para-aminosalicylic acid throughout the study. If serious life-threatening infection
present, patients’ entry into study was postponed until it was eradicated. People with
history of peptic ulcer, active peptic ulcer disease, or gastrointestinal bleeding were in-
cluded
Severity of disease: not clearly described; however, participants probably had moderate-
to-severe alcoholic hepatitis, since they presented people with alcoholic hepatitis who
met the described criteria
Exclusion criteria
People treated with adrenocorticosteroid in the 6 months prior to admission or who
showed evidence of psychotic behaviour precluding their co-operation
Randomisation procedure
Random, sealed-envelope technique
Number of participants randomised: 33
Prednisolone group: n = 17
Control group: n = 16
Interventions Experimental group: oral prednisolone 10 mg 4 times a day for 14 days, 5 mg 4 times
a day for 4 days, 2.5 mg 4 times a day for 4 days, and 2.5 mg twice a day for 4 days
Control group: placebo tablets; same schedule as prednisolone group
Additional interventions to the trial groups: participants encouraged to eat standard
hospital 2600-calorie diet and were offered supplements when caloric intake seemed
inadequate. Low-protein, low-sodium, and other special diets used as clinical situation
dictated
Duration of treatment: 26 days
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Blitzer 1977 (Continued)
Follow-up after randomisation: 9 weeks
Outcomes Mortality
Liver biochemistry
Liver histology
Adverse events
Notes Quote: “There were no significant differences between them [participants] with respect
to mean age, sex, race, duration of hospitalization prior to entry into the study, frequency
of histologically proved cirrhosis, or to the histologic severity of the alcoholic hepatitis.”
Letter sent to authors in March 2000. No answer received. No further attempts were
made as the trial was conducted between 1971 and 1973
1 participant received placebo treatment during trial. At the end of the therapy, due to
lack of improvement, the ward physician requested the code be broken. The participant
received a 7-day course of prednisolone. He died 17 days later; his death was included
in the mortality data of the control group on an intention-to-treat basis
On the 26th day of treatment, 3 participants in control group and1 in glucocorticosteroid
group received the alternative medication on a double-blind basis
Quote: “Both prednisolone and placebo tablets were kindly supplied by the Upjohn Co.
, Kalamazoo, Michigan.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned by random,
sealed-envelope technique to receive either
placebo or steroid.”
Allocation concealment (selection bias) Low risk Quote: “… sealed-envelope technique to
receive either placebo or steroid.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Only the pharmacist was aware of
the type of therapy which any individual
patient was receiving.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “5 participants, who had each re-
ceived less than 5 days of therapy, were sub-
sequently excluded from analysis. Of these,
three had left the hospital against medi-
cal advice or withdrew from the study, and
in two participants experimental therapy
had been stopped following gastrointesti-
nal haemorrhage. One bled after 4 days of
therapy from a gastric varix and the other
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Blitzer 1977 (Continued)
from an unknown site after three days of
treatment. On breaking the code at the end
of the investigation, it was learned that all
five participants had been in the steroid
group…Furthermore, the addition of two
deaths among the five excludedparticipants
…”
3/17 (9%) people in prednisolone group
and 0/16 (0%) people in control group
dropped out
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk None suspected
Bories 1987
Methods Randomised controlled trial
Country: France
Dates: 1979-1982
Intention-to-treat analysis: yes
Sample size calculation: not reported.
Participants Demographic characteristics
Age (mean): prednisolone group: 41 years (range 26 to 68 years); control group: 49 years
(range 30 to 70 years)
Sex: prednisolone group: 16 men and 8 women; control group: 11 men and 10 women
Inclusion criteria and degree of severity
Not stated clearly, but mean level of bilirubin ≥ 147 (SD 30.78) mmol/L
Alcohol consumption: men: 155 (SD 46) g/day; women: 140 (SD 32) g/day
Exclusion criteria
48 excluded due to infections (n = 45), diabetes (n = 2), and tuberculosis (n = 1)
Randomisation procedure
Random number table
Number of participants randomised: 45
Prednisolone group: n = 24
Control group: n = 21
Interventions Experimental group: oral prednisolone 40 mg/day
Control group: no intervention
Additional interventions to the trial groups: 1500 calories and protein 50 g/day.
Encephalopathy treated with lactulose and neomycin. In case of infection, participants
received antibiotics
Duration of treatment: 1 month
Duration of follow-up: 3 months after randomisation
44Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bories 1987 (Continued)
Outcomes Mortality
Liver histology
Adverse events
Notes Letter sent to authors in March 2000. No answer received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “By random number table.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk None suspected
Campra 1973
Methods Prospective randomised control trial
Country: USA
Date: 1971
Intention-to-treat analysis: no
Sample size calculation: not reported
Participants Demographic characteristics
Age (mean): prednisolone group 43.1 (SD 11.1) years; control group 42.7 (SD 8.1) years
Sex: prednisolone group: 40 (8%) men; control group: 35 (9%) men
Inclusion criteria and degree of severity
Clinical diagnosis of severe acute alcoholic liver disease, absence of contraindication to
corticosteroids therapy, no history of liver disease
Liver biopsy not required for inclusion since some participants had prothrombin time <
50% of normal value
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Campra 1973 (Continued)
Severity of disease: no clear definition
Exclusion criteria
People with other known illness or illnesses
Randomisation procedure
Previously prepared sealed envelopes
Number of participants randomised: 50 participants entered trial, but 5 subsequently
withdrawn when additional data favoured another diagnosis. 45 analysed (see ’Risk of
bias’ table)
Prednisolone group: n = 20
Control group: n = 25
Interventions Experimental group: oral prednisone 0.5 mg/kg bodyweight daily for 3 weeks; then 0.
25 mg/kg bodyweight daily for 3 weeks
Control group: no intervention
Additional interventions to the trial groups: vitamin supplements, folic acids; high
calorie, high protein diet if tolerated. In people with encephalopathy, protein intake was
reduced to 20 g or 40 g and neomycin 500mg 4 times daily was given. In case of bleeding,
vomiting, and extreme anorexia, people received 5% or 10% dextrose solutions
Duration of treatment: 6 weeks
Duration of follow-up: hospital stay after randomisation: prednisolone group: 42-92
days, mean 47 days; control group: 43-95 days, mean 48 days
Outcomes Mortality
Liver biochemistry
Liver histology
Adverse events
Notes Letter sent to authors in March 2000. AG Redeker answered in January 2001 (see the
’Risk of bias’ table)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “… using previously prepared
sealed envelopes, patients were randomly
allocated to one of the two treatment
groups.”
Allocation concealment (selection bias) Low risk Information obtained through personal
communication with the authors in 2001
read: “they [envelopes] were never in the
possession of the investigators, but were
kept by the department secretary who
opened them upon request.”
However, the publication reads: “using pre-
viously prepared sealed envelopes, patients
were randomly allocated to one of the two
treatment groups.”
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Campra 1973 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “the trial was not double blind.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “… all statistical analyses and in-
terpretation were done under supervision
of Dr. John Weiner of the Department of
Biostatics, University of Southern Califor-
nia School of Medicine.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “50 patients entered the trial, but
fivewere subsequentlywithdrawnwhen ad-
ditional data favoured another diagnosis. In
one case (group 2), jaundice proved to be
caused by hepatitis B … the patient died
… 2 of these patients were in group 2, one
patient in group 1; all survived. The fifth
patient was removed from the trial when
peptic ulcer was diagnosed after 15 days of
prednisolone therapy.”
Total: prednisolone group: n = 22; control
group: n = 28
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk Not suspected
Carithers 1989
Methods Randomised, multicentre, double-blind, placebo-controlled, clinical trial
Country: USA
Dates: 1979-1984
Intention-to-treat analysis: yes
Sample size calculation: reported (calculated that 62 patients should be entered to have
95% chance of detecting a difference in survival between the 2 groups)
Participants Demographic characteristics
Age (mean): methylprednisolone group: 43.1 (SD 2.0) years; control group: 44.4 (SD
1.7) years
Sex: methylprednisolone group: 20 (57%) men; control group: 21 (68%) men
Inclusion criteria and degree of severity
History of long-standing alcoholism and clinical features of alcoholic hepatitis evaluated
by 1 principal investigator within 3 days of admission; clinical evidence of spontaneous
hepatic encephalopathy (assessed using standard clinical criteria and present when cor-
rectable causes of encephalopathy had been excluded) or a discriminant function value >
32 or both; negative hepatitis B surface antigen within the first 3 days of hospitalisation;
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Carithers 1989 (Continued)
and no history of previous viral hepatitis
Exclusion criteria
Gastrointestinal haemorrhage requiring transfusions; diabetes requiring insulin admin-
istration; active infection requiring treatment; clinical and laboratory evidence of acute
pancreatitis; history of recent head trauma; known prior heroin addiction; or pre-existing
chronic renal disease with a serum creatinine > 175 mmol/L
Randomisation procedure
Random code sequence generated and kept by an independent source (see ’Risk of bias’
table)
Number of participants randomised: 67
Prednisolone group: n = 36 (2 refused, 1 was excluded from analysis); 33 analysed
Control group: n = 31
Interventions Experimental group: methylprednisolone 32 mg/day (equivalent to 40 mg pred-
nisolone). Single dose of 8 tablets of 4 mg each morning for 28 days
In participants unable to take oral medications, intravenous infusions of study drug
administered daily (methylprednisolone sodium succinate (SoluMedrol) or identical
placebo. After 4 weeks, 4 tablets administered daily for 1 week followed by 2 tablets daily
for 1 week; then therapy discontinued
Control group: placebo; identical tablets
Additional treatment: participants offered 3000-caIorie diet. Protein (1-1.5 g/kg body-
weight) provided when no evidence of hepatic encephalopathy. Protein restricted to≤ 20
g/day and lactulose therapy instituted in participants with signs of hepatic encephalopa-
thy. Ascites managed with sodium restriction or by addition of spironolactone in partic-
ipants who did not respond with diuresis within 5 days
Fluid intake restricted in participants with hyponatraemia. B-compIex multivitamins
and folic acid 1 mg given daily. Participants who developed tremulousness or delirium
tremens received diazepam or oxazepam
Duration of treatment: 5 weeks; 28 days at 32 mg/day then 16 mg/day for 7 days
Duration of follow-up after randomisation: at discharge
Outcomes Mortality
Liver biochemistry
Adverse events
Notes Letter sent to authors in March 2000. No answer received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “… Random sequences for drug
or placebo were submitted to the Upjohn
Company (Kalamazoo, Michigan), which
provided methylprednisolone (Medrol) in
4-mg tablets and identical placebo tablets as
well as intravenous preparations of methyl-
prednisolone sodium succinate (SoluMe-
drol) and placebo. A random code was pre-
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Carithers 1989 (Continued)
pared for each of the four participating
institutions such that within each group
of 10 patients, 5 would receive methyl-
prednisolone and 5 placebo. The random
code sequence was kept by an independent
source.”
Allocation concealment (selection bias) Low risk Quote: “the random code sequence was
kept by an independent source.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “neither the principal investigators
nor their associates were aware of which
regimen patients received throughout the
trial.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Data obtained at initial evaluation
and follow-up were recorded on standard-
ized data collection forms thatwere submit-
ted to the statistical coordinating center at
the end of each study … A study overview
committee, chaired by Dr. Hyman Zim-
merman, reviewed the ongoing results of
the study on a yearly basis from reports gen-
erated by the statistical coordinating cen-
ter, which had access to the randomisation
codes.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3%
Quote: “One patient who receivedmethyl-
prednisolone was belatedly discovered to
have had neither encephalopathy nor ele-
vation of discriminant function sufficient
to meet the entry criteria and was excluded
from analysis. Of the remaining 66 pa-
tients, 64 remained in the hospital for the
duration of the study. Two methylpred-
nisolone recipients refused to continue in
the study. The first patient signed out of
the hospital after 10 days on the trial and
was alive at the end of the study. The sec-
ond patient was discharged at his insistence
after 15 days on the trial and was given the
study drug to take at home, but he never re-
turned for follow-up. His status at the end
of the study was unknown. Hewas the only
patient lost to follow-up.”
Prednisolone group: 2/36; control group:
0/31
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Carithers 1989 (Continued)
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk Not suspected
De 2014
Methods Randomised controlled clinical trial
Country: Medical College and Hospital, Kolkata, India
Dates: January 2010 to August 2012
Study protocol approved by the institutional ethical committee
Participants Demographic characteristics
Age (mean): pentoxifylline + prednisolone group: 42.73 (SD 0.43) years; pentoxifylline
group: 41.33 (SD 7.81) years
Sex: 100% men
Inclusion criteria and degree of severity
History of chronic alcohol intake > 50 g/day with clinical and biochemical features of
severe alcoholic hepatitis (MDF score ≥ 32 and AST:ALT > 2:1 with absolute value of
AST < 500 IU/L and ALT < 200 IU/L
MELD score, GAHS, and Child-Pugh score calculated for all included participants
Exclusion criteria
Other potential aetiology of liver injury (acute or chronic viral hepatitis, autoimmune
liver disease, Wilson’s disease) even in the background of chronic alcohol intake, positive
for HIV antibodies or history of abstinence from alcohol in the last month, infection,
sepsis or spontaneous bacterial peritonitis, acute pancreatitis, gastrointestinal bleeding,
hepatorenal syndrome or any other severe associated disease such as uncontrolled diabetes
mellitus, systemic hypertension, heart failure, pulmonary disease or malignancy at the
time of inclusion or in the previous 3 months
Randomisation procedure
Computer-generated randomisation table
Number of participants randomised: 62
Pentoxifylline + prednisolone group: n = 31 (1 voluntary dropped out)
Pentoxifylline group: n = 31 (1 vertigo and withdrew)
Interventions Experimental group: prednisolone (Wysolone, Wreath, Mumbai, India) 40 mg once
daily for 4 weeks + pentoxifylline (Trental tablets, Sanofi Aventis, Mumbai, India) tablets
400 mg 3 times daily for first 4 weeks
Control group: placebo tablet for 4 weeks + pentoxifylline 400 mg 3 times daily orally
first 4 weeks
Duration of treatment: 11 weeks (12 weeks in group 1 (the control) and 11 weeks in
group 2 (the experimental))
Quote: “After the initial 4 weeks, the study was opened and the patients allocated to
different groups were revealed. Patients in Group 1 (PTX [pentoxifylline]) who tolerated
the drug well, continued to receive the medication at the same dose for the next 8 weeks
and then stopped
After 4 weeks of initial therapy, the dose of prednisolone in Group 2 was tapered by 5
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De 2014 (Continued)
mg/week over a period of 7 weeks and then stopped and received PTX like Group 1
patients.” (Thus, we could use only 3 months.)
Duration of follow-up: 12 months
Outcomes Mortality
Adverse events
Morbidity
Notes Quote: “One patient in Group 1 developed severe vertigo within 7 days after starting
PTX, and one patient in Group 2 withdrew voluntarily from the study and hence they
were excluded. A total of 60 patients, 30 in each group, were considered for the final
analysis.”
Letter sent to SK Mandal 12 December 2016. No reply received
Quote: “Prednisolone tablet (Wysolone, Wreath, Mumbai, India) and PTX (trental
tablets, Sanofi Aventis, Mumbai, India”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The recruited patients were then
divided into 2 groups by a computer gen-
erated randomization table.”
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The investigator, who allocated
the patients to the groups, administered the
drugs and collected the clinical and labo-
ratory data, as well as statisticians were all
blinded regarding the nature of the phar-
macotherapy.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “as well as statisticians were all
blinded regarding the nature of the phar-
macotherapy.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1.6%
Quote: “One patient in Group 1 devel-
oped severe vertigowithin 7days after start-
ing PTX [pentoxifylline], and one patient
in Group 2 withdrew voluntarily from the
study and hence they were excluded.”
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
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De 2014 (Continued)
Other bias Low risk Not suspected
Depew 1980
Methods Randomised, double-blind, controlled clinical trial
Country: USA
Dates: 1977-1979
Study approved by the Human Experimentation Committee of the JohnWesley County
Hospital
Intention-to-treat analysis: yes
Sample size calculation: reported
Participants Demographic characteristics
Age (mean): prednisolone group: 49.8 (SD 2.1) years; control group: 48.2 (SD 2.3) years
Sex: prednisolone group: 10 (67%) men; control group: 6 (43%) men
Hepatic encephalopathy: prednisolone group: 100%; control group: 100%
Ascites: prednisolone group: 87%; control group: 92%
Inclusion criteria and degree of severity
Alcohol abusers from lower socioeconomic strata with a clinical diagnosis of severe
alcoholic hepatitis manifested by hepatomegaly, leukocytosis, and a serum bilirubin >
5 mg/dL, spontaneous hepatic encephalopathy occurring in absence of gastrointestinal
haemorrhage, sedation, diuretic usage, or major electrolyte disturbances
Exclusion criteria
Quote: “Severe diabetes, active tuberculosis, and serious bacterial infection prevented
participation in the trial”
Liver biopsy was not required.
Randomisation procedure
Unclear as not described (see ’Risk of bias’ table)
Number of participants randomised: 28
Prednisolone group: n = 15
Control group: n = 13
Interventions Prednisolone group: prednisolone 40 mg daily orally
Control group: placebo
Additional treatment: supportive measures were attention to fluid and electrolyte bal-
ance, multiple vitamin supplementation, and parenteral glucose administration when
food intake was poor. Encephalopathy treated with catharsis, protein restriction, and
oral neomycin
Duration of treatment: 28 days followed by tapered withdrawal over the ensuing 14
days
Duration of follow-up: 6 weeks
Outcomes Mortality
Liver biochemistry
Liver histology
Adverse events
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Depew 1980 (Continued)
Notes Letter sent to authors in March 2000. No answer received. No further attempts were
made as the trial was conducted between 1977-1979
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Quote: “All patients fulfilling the crite-
ria who gave informed consent were ran-
domised into two treatment protocols” and
“… to avoid introducing bias based on the
presence of the hepatorenal syndrome, the
randomisation procedure was stratified to
distinguish those with a serum creatinine
greater than 2.5 mg/dL.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Neither the principal investigators
nor the physicians attending the patients
were aware of the identity of the coded
drugs. Provision was made for breaking
the code if serious complications developed
which could be related to steroid therapy.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals and dropouts
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk None suspected
Helman 1971
Methods Randomised controlled trial
Country: USA
Intention-to-treat analysis: yes
Sample size calculation: not reported
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Helman 1971 (Continued)
Participants Demographic characteristics
Age (mean): 47.8 years (range 30-67 years)
Sex: 12 men and 25 women
Inclusion criteria and degree of severity
Diagnosis of alcoholic hepatitis confirmed by percutaneous needle biopsy. 70% of partic-
ipants had anaemia on admission attributed to folate deficiency, blood loss, alcoholism,
and haemolysis
Exclusion criteria
Biopsy could not be obtained within the first week of hospitalisation, gastrointestinal
bleeding requiring transfusion, or if PPD was positive
Authors reported that participants were classified into three groups, according to clinical
severity of their disease. Quote: “Group I were severely ill - manifesting precoma or
coma, group 2 were moderately ill, but no evidence of encephalopathy, group 3 were
asymptomatic ambulatory patients.”
Randomisation procedure
Random, double-blind technique. Determined by hospital pharmacist, without inform-
ing physicians, nurses, or patients until completion of the study
Number of participants randomised: 37, divided in 3 groups according to severity of
disease
Prednisolone group: n = 20
Control group: n = 17
Interventions Experimental group: prednisolone 40 mg daily
Control group: daily lactose placebo
Additional intervention: bed rest, high-protein (100 g) and high-calorie diet (3000 kcal)
when tolerated and vitamin supplementation including folic acid. Sodium restriction
instituted and all participants with ascites and oedema were treated with diuretics
Duration of treatment: 6 weeks: 4 weeks and 2-week period tapered
Duration of follow-up after randomisation: 4 months
Outcomes Mortality
Liver biochemistry
Liver histology
Adverse events
Notes Quote: “tablets 40 mg of prednisolone daily or lactose placebo (provided by Upjohn Co,
Kalamazoo, Mich).”
Letter sent to authors in March 2000. No answer received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Quote: “patients were selected by a ran-
dom, double-blind technique …”
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Helman 1971 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Drug treatment was randomly de-
termined by the hospital pharmacist, with-
out informing physicians, nurses, or pa-
tients until completion of the study.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “…The treatment codewas broken
during the study in only one case because
of a medical emergency.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals or dropouts
Selective reporting (reporting bias) High risk No protocol available. However, all-cause
mortality and liver-related mortality were
reported
Other bias Low risk
Maddrey 1978
Methods Randomised, double-blind clinical trial with parallel-group design (3 groups)
Country: USA
Intention-to-treat analysis: no
Sample size calculation: not reported
Participants Demographic characteristics
Age (mean): prednisolone group: 40 (SD 8.5) years; control group: 42.3 (SD 11.1) years
Sex: prednisolone group: 12 (50%) men; control group: 23 (74%) men
Inclusion criteria and degree of severity
History of long-standing and recent alcoholism referred to Liver Service (The Johns
Hopkins Hospital). Percutaneous liver biopsy performed unless precluded by coagula-
tion abnormalities. Alcoholic hepatitis defined histologically as an inflammatory hepatic
disease with cell swelling and hydropic change, cell necrosis, and polymorphonuclear
leukocytic infiltration
Exclusion criteria
Active gastrointestinal haemorrhage, pancreatitis, history of peptic ulcer, active infection,
presence of hepatitis B infection, or history of previous viral hepatitis. MDF. People had
wedged hepatic venous pressure determination
Randomisation procedure
Random drug sequences
Number of participants randomised: 57
Participants randomised into 3 groups based on apparent severity of disease
GroupA (moderately ill), serumbilirubin > 3mg/dL; hepatomegaly; and clotting factors
adequate to allow liver biopsy
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Group B (more severely ill), hyperbilirubinaemia and hepatomegaly as in A with addi-
tional presence of ascites or hepatic encephalopathy (or both), but coagulation studies
adequate for liver biopsy
Group C (severely ill), hyperbilirubinaemia and hepatomegaly as in A and B, with
or without ascites or hepatic encephalopathy (or both), but coagulation abnormalities
precluded liver biopsy
Prednisolone group: n = 25
Control group: n = 32
Interventions Experimental group: prednisolone 40 mg/day orally; 8 × 5-mg tablets every morning
Control group: identical placebo tablets
Additional interventions to the trial groups: offered 3000 calorie diet. Protein 1-1.5
g/kg provided for people with no evidence of hepatic encephalopathy. In people with
encephalopathy, protein restriction to≤ 20 g/day and lactulose therapy. Ascites managed
with sodium restriction alone or with the addition of spironolactone in people who did
not respond with diuresis in 5 days. All participants initially received thiamine 100 mg
intramuscularly. B-complex multivitamins and folic acid given daily
Duration of treatment: 28-32 days
Follow-up: until discharge
Outcomes Early mortality
Complications of therapy
Liver function and haematological tests
Wedged hepatic venous pressure
Factors associated with a fatal outcome
Discriminant function analysis
Notes Study supported by Research Grant AA00201 from the National Institute of Alcohol
Abuse and Alcoholism of the National Institutes of Health, and by Grant RR-35 from
the Clinical Research Centers Program, United States Public Health Service.
Prednisolone and placebo tablets provided by the Division of Steroid Research, The
Upjohn Company, Kalamazoo, Mich. However, no further details were provided
Letter sent to authors in March 2000. No answer received. No further attempts made
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised for
treatment within three groups based on ap-
parent severity of disease. Random drug se-
quences were arranged within each group.
”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Prednisolone (5 mg) or identical
placebo tablets were given in a single dose
of 8 pills each morning for 28 to 32 days.
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(Prednisolone (5mg) and identical placebo
tablets were provided by the Division of
Steroid Research, The Upjohn Company,
Kalamazoo, Mich.). The investigators were
not aware of which regimen the patient was
receiving until the completion of the study.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3.5% dropped out or were withdrawn.
Quote: “Two additional patients were re-
moved from the study after randomisa-
tion. One patient who was randomised to
the placebo group bled from oesophageal
varices before receiving the study drug.
He subsequently stopped bleeding and sur-
vived. Another patient had an episode of
upper gastrointestinal haemorrhage pre-
sumably from oesophageal varices after re-
ceiving prednisolone for 9 days and the
drug was stopped.”
Prednisolone group: 1/25; control group:
1/32
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk None suspected
Mendenhall 1977
Methods Prospective, randomised clinical trial (3 intervention groups)
Country: USA
Intention-to-treat analysis: not mentioned
Sample size calculation: not reported
Participants Demographic characteristics
Age: not reported
Sex: not reported; most probably men as they came from V.A. (Veteran Affairs) Medical
Centers
Inclusion criteria and degree of severity
History of daily ethanol ingestion > 100 g/day for ≥ 1 year; hepatomegaly (> 12 cm)
and significant jaundice (bilirubin > 5 mg %). Liver biopsy obtained in about 70% of
participants to confirm diagnosis
Exclusion criteria
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Not described
Randomisation procedure
Not described, but mentioned that “regimens were chosen randomly and blinded so that
neither physician nor patient was aware of the treatment modality.”
Number of participants randomised: 46
Prednisolone group: n = 12 (all severe alcoholic hepatitis)
Control group: n = 17 (all severe alcoholic hepatitis)
Oxandrolone group: n = 17
Interventions Experimental group: prednisolone 60 mg/day × 5, then decreased over a 16-day period
Control group: placebo
Experimental group 2: oxandrolone (not included in the review)
Additional treatment: supportive care
Duration of treatment: 21 days
Duration of follow-up: to discharge
Outcomes Mortality
Liver biochemistry
Notes Letter sent to study authors in 2006. No answer received.
Only published as an abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “… regimens were chosen ran-
domly.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “blinded so that neither physician
nor patient was aware of the treatment
modality.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “one additionalmortality withdrew
from the study on the 8 day” (not men-
tioned from what group out of 50 partici-
pants
17 participants treated with oxandrolone
Selective reporting (reporting bias) High risk No protocol available. However, all-cause
mortality was reported
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Other bias Low risk None suspected
Mendenhall 1984
Methods Co-operative, multicentre, randomised clinical trial (3 intervention groups)
Country: USA
Dates: 1980-1983
Intention-to-treat analysis: yes
Sample size calculation: reported
Participants Demographic characteristics
Age (mean): prednisolone group: 51.5 (SD 8.2) years; control group 50.4 (SD 9.2) years
Sex: 100% men
Inclusion criteria and degree of severity
Men hospitalised at 6 Veterans Administration Medical Centers in whom diagnosis of
moderate or severe alcoholic hepatitis was based on conventional clinical and laboratory
changes of this disease. Histological confirmation not required, so severely ill people
not excluded. Severity classified by degree of jaundice (bilirubin) and coagulopathy
(prothrombin time)
Exclusion criteria
Conditions that contradicted corticosteroid therapy: severe infections, active peptic ulcer
disease, or insulin-dependent diabetesmellitus, or if they had taken corticosteroids within
the preceding 3 months; positive test for hepatitis B surface antigen; clinical or historical
evidence of recent parenteral drug abuse, intractable congestive heart failure, neoplasms
that commonly metastasise to the liver, or non-alcoholic liver diseases
Randomisation procedure
Assignmentmade byCoordinatingCenter (Hines, Ill) was balancedwithin each hospital,
and according to disease severity
Number of participants randomised: 178 (prednisolone and placebo) + 85 (n = oxan-
drolone)
Prednisolone group: n = 90 (moderate 46, severe 44)
Control group: n = 88 (moderate 45, severe 43)
Oxandrolone group: 85
Interventions 132 participants with moderate disease and 131 with severe disease were randomly
assigned to 1 of 3 treatments: prednisolone, oxandrolone, or placebo
Experimental group: prednisolone
Dose: 60 mg/day for 4 days; 40 mg/day for 4 days; 30 mg/day for 4 days; 20 mg/day
for 4 days; 10 mg/day for 7 days; 5 mg/day for 7 final days
Control group: placebo
Experimental group 2: oxandrolone (not included in the review)
Duration of treatment: 30 days
When possible, participants were evaluated monthly at outpatient clinics. If alcoholic
hepatitis recurred and required rehospitalisation, the person was reassigned to the same
therapy for 30 days with his permission
Duration of follow-up after randomisation: 1 year (350 days for prednisolone group)
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Outcomes Mortality
Liver complications
Liver biochemistry
Adverse events
Notes Matching placebos prepared by Upjohn Company and G.D. Searle and Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Treatment assignment was made
by the Coordinating Center (Hines, Ill.).
The random assignment of treatments was
balanced within each hospital, as well as
according to disease severity.”
Allocation concealment (selection bias) Low risk Quote: “Treatment assignment were made
by the Coordinating Center (Hines, Ill).”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Medication was packed into unit
dose kits at the Veterans Administra-
tionCenter Pharmacy(Albuquerque,N.M.
). The patient, physician and the local hos-
pital pharmacy had no knowledge of the
specific medication in use.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4.5%
Quote: “Ten patients withdrew from the
study before completing treatment (5 given
placebo, 3 prednisolone). However, these
patients were included in the outcome as-
sessment.”
Prednisolone group: 3/90; control group:
5/88
Quote: “324 days … 37 patients were lost
to follow-up: 13 given placebo, 11 pred-
nisolone.”
Selective reporting (reporting bias) High risk No protocol available. However, all-cause
mortality and liver-related mortality were
reported
Other bias Low risk None suspected
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Methods Prospective, double-blind, controlled pilot trial
Country: USA
Intention-to-treat analysis: no
Sample size calculation: not reported
Participants Demographic characteristics
Age (mean): prednisolone group: 44.6 (SD 4.4) years; control group: 49.5 (SD 8.9)
years; overall range 27-61 years)
Sex: prednisolone group: 13 (64%) men; control group: 7 (67%) men
Inclusion criteria and degree of severity
History of recent heavy alcohol ingestion, serum bilirubin concentration ≥ 5 mg/100
mL, clinical and laboratory deterioration over the first 5 hospital days, striking lack of
improvement in the patient’s clinical and biochemical status over first 5 hospital days,
or rapid marked deterioration in < 24 hours
For admission to the study all three absolute criteria were required. In addition, ≥ 2
major criteria or 1major and≥ 4minor criteria had to bemet.Major criteria: liver biopsy
showing alcoholic hepatitis; hepatic encephalopathy (including asterixis); persistent or
progressive azotaemia not explained by another process; and total bilirubin levels > 20
mg/100 mL. Minor criteria: fever not obviously secondary to another process; white
blood count > 12,000 not obviously secondary to another process; anorexia or nausea
or vomiting; palpable hepatomegaly; palpable splenomegaly; oesophageal varices; spider
angiomas, oedema or ascites; palmar erythema; and prothrombin time prolonged ≥ 3
seconds over control
The Australia antigen was absent from the serum of all 16 participants in whom it was
sought. Before the trial, a percutaneous needle biopsy of the liver was performed if the
prothrombin time was not prolonged >4 seconds over control and there was no clinical
bleeding tendency
Exclusion criteria
Active gastrointestinal bleeding, pancreatitis, radiological evidence of peptic-ulcer dis-
ease, active or questionably active pulmonary tuberculosis, and potentially life-threaten-
ing bacterial infection
Randomisation procedure
Number drawn from a pool
Number of participants randomised: 23 (20 analysed). 23 accepted to participate,
but 3 died within 36 hours of start of therapy, and were excluded from analysis before
code was broken, and did not receive adequate medication. Final series consisted of 20
participants
Prednisolone group: n = 11
Control group: n = 9
Interventions Prednisolone group: 6-methyl-prednisolone 50 mg (equivalent to prednisolone 50 mg,
or hydrocortisone 200 mg) in 3 divided doses, parenterally for the first 10 days. If clinical
improvement occurred over this interval and if nausea and vomiting were absent the
drug was administered orally, and the dose gradually tapered (decreased every second
day by 4 mg for the 11th to the 18th days, by 2 mg for the 19th to 30th days and every
third day by 2 mg for the 31st to 45th days). If there was no clinical improvement within
10 days, the initial parenteral dose of 40 mg daily was continued until improvement or
death occurred
Control group: placebo (lactose)
Additional treatment: early in study only participants with a positive intermediate
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strength PPD test or a suspicious chest x-ray were given isoniazid; however, later in
study, all participants received isoniazid. Received general supportive care required in
hepatic decompensation. Special attention given to fluid and electrolyte balance, prompt
treatment of hepatic encephalopathy, and repeated evaluation for infection. Most par-
ticipants had daily estimation of the caloric and protein intake by a hospital dietitian.
People unable to take oral nutrition received glucose ≥ 400 calories/day parenterally
Duration of treatment and of follow-up: 45 days after randomisation
Outcomes Mortality
Liver biochemistry
Liver histology
Adverse events
Notes Country: USA
Letter sent to study authors in March 2000. No answer received
Quote: “Twenty-three patients were accepted for studying. However, three died within
36 hours of the start of the therapy Quote: and were excluded from analysis before the
code was broken because they did not receive adequate medication.”
Supported in part by a gastroenterology-research training grant (AM-05099) from the
National Institute of Arthritis and Metabolic Diseases (a portion of this work was con-
ducted within the Clinical Research Center of the University of Washington, with sup-
port by a grant MO1 FR-37 from the National Institutes of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the case was randomised into one
of the two treatment groups. Both the
steroid (6-methyl prednisolone, orMedrol)
and the placebo (lactose) were packaged
and coded by number in both parenteral
and oral forms (prepared and supplied
through the courtesy of the Upjohn Co,
Kalamazoo, Mich) and randomisation was
achieved by a number drawn from a
pool. Neither patients nor physicians knew
which form of treatment was used until the
study had been completed, when the code
was broken.”
Allocation concealment (selection bias) Low risk Quote: “the case was randomised into one
of the two treatment groups. Both the
steroid (6-methyl prednisolone, orMedrol)
and the placebo (lactose) were packaged
and coded by number in both parenteral
and oral forms (prepared and supplied
through the courtesy of the Upjohn Co,
Kalamazoo, Mich) …”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Neither patients nor physicians
knew which form of treatment was used
until the study had been completed, when
the code was broken.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “At the conclusion of the study, all
needle biopsy and post-mortem liver spec-
imens were coded and read in blind review
by the same observer.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 13%
Quote: “Twenty three patients were ac-
cepted for study, three diedwithin 36 hours
of the start of therapy and were excluded
from analysis before the code was broken
because they didn’t receive adequate medi-
cation. The final series thus consisted of 20
patients.”
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk None suspected
Ramond 1992
Methods Randomised, double-blind trial
Country: France
Dates: March 1987 to June 1990
Intention-to-treat analysis: yes
Study approved by hospital ethics committees
Participants Demographic characteristics
124 people with alcohol dependence were admitted to 2 centres
Age (mean): prednisolone group: 48.1 (SD 1.3) years; control group: 48.2 (SD 1.6) years
Sex: prednisolone group: 10 men; control group: 9 men
Randomisation procedure
Computer-generated random code
Inclusion criteria and degree of severity
Biopsy-confirmed alcoholic hepatitis (characterised by hyaline necrosis and infiltration
of polymorphonuclear leukocytes) and spontaneous hepatic encephalopathy or a MDF
> 32 (or both)
8 people died before inclusion in the trial.
Exclusion criteria
Gastrointestinal bleeding or bacterial infection excluded unless they could be effectively
treated within 48 hours; presence of hepatitis B surface antigen; presence of HIV anti-
bodies; refusal of liver biopsy; non-alcoholic hepatitis at histology
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Number of participants randomised: 65 (4 excluded) (see ’Notes’)
Prednisolone group: n = 33 (32 analysed)
Control group: n = 32 (29 analysed)
Interventions Prednisolone group: prednisolone (Solupred) 40 mg (prednisolone 40 mg equivalent
methylprednisolone 32 mg) given in single dose of 2 tablets each morning for 28 days.
If participant was unable to take oral medication, received intravenous infusions of
prednisolone (Hydrocortancyl)
Control group: single dose of 2 tablets
Additional treatment: provided with 3000 kcal containing 1 g protein/kg. Participants
with hepatic encephalopathy received lactulose therapy. Ascites managed with sodium
restriction or by adding spironolactone to the treatment regimen. Received B complex
multivitamins, folic acid, and antacids daily
Duration of treatment: 28 days
Duration of follow-up: 8 weeks
Outcomes Mortality
Liver biochemistry
Adverse events
Notes Letter sent to study authors in March 2000. No answer received
Trial stopped at the first interim analysis after inclusion of 61 out of the planned 130
participants. Authors used an alpha error < 0.025. This is too high a value to prevent
early stopping at a random high
Quote: “Drug therapy was interrupted by the attending physician if there was severe
bacterial infection or gastrointestinal bleeding, or if a corticosteroid-related complication
was suspected … in patients with such complications the remaining tablets of the study
drug were replaced with placebo tablets provided by the pharmacist (the only person
who knew which regimen the patient had received first). The principal investigator and
their associates were not aware of randomisation procedure or of the medication that the
patients were receiving throughout the trial.”
Quote: “65 patients were randomly assigned, but 4 were excluded - one patient assigned
to receive prednisolone was found to have anguilluliasis and her treatment was stopped
one day after her inclusion in the study. Three patients assigned to placebo were found
not to have satisfied the inclusion criteria. These 4 patients were alive at the end of
treatment.”
Prednisolone tablets and placebo were provided by Laboratoire Houdé (Paris)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a random code was prepared by
computer for each participating centre …
There was a different code prepared for
men and women in each center, so that
within each group of six patients (male
and female), three patients received pred-
nisolone and three received placebo.”
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Allocation concealment (selection bias) Low risk Quote: “a random code was prepared by
computer for each participating centre.
Random sequences of drug or placebowere
prepared by the pharmacist at each hospi-
tal.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “a random code was prepared by
computer for each participating centre.
Random sequences of drug or placebowere
prepared by the pharmacist at each hospi-
tal.”
Quote: “prednisolone (Solupred) in 20 mg
tablets and identical placebo were provided
by the pharmacists at each hospital.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1.5%
1 woman left the hospital and then “she
was re hospitalised 56 days after enrolment
and left again the following day. She was
the only patient lost to follow up.”
Prednisolone group: 1/33; control group:
0/32
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk Not suspected
Richardet 1993
Methods Randomised clinical trial with a cross-over design
Country: France
Intention-to-treat analysis: not mentioned
Sample size calculation: not reported
Participants Demographic characteristics
No information
Inclusion criteria and degree of severity
Non-infected people with histologically confirmed alcoholic hepatitis. All participants
had severe hepatic failure (prothrombin time < 50%, or bilirubin > 5.6 mg/dL, or
encephalopathy)
Randomisation procedure
Not mentioned
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Number of participants randomised: 23
Glucocorticosteroid group: n = 12
Control group: n = 11
Interventions Prednisolone group: prednisolone 40 mg daily
Control group: placebo 40 mg daily
Duration of treatment:
Prednisolone group: 1 week of treatment followed by 1 week of no treatment
Control group: 1 week of no treatment followed by 1 week of treatment
After that, both groups received glucocorticosteroids for 3 weeks
Duration of follow-up: at discharge from hospital (3 months)
Outcomes Mortality
Liver biochemistry
Notes Letter sent to study authors in 2006. No answer received.
Only published as abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk No information
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Methods Prospective, double-blind, randomised clinical trial
Country: USA
Intention-to-treat analysis: not mentioned, but presumably used
Sample size calculation: not reported.
Participants Demographic characteristics
Age (mean): prednisolone group/control group: 45,5/44,5
Sex: prednisolone group: 25% men; control group: 44% men
Inclusion criteria and degree of severity
History of recent heavy alcoholic ingestion, serum bilirubin > 5 mg %, hospitalisation
for ≥ 5 days without improvement in liver tests; or rapid deterioration of the clinical
condition during a 24-hour period while under observation. In addition, minimum of 2
major criteria or 1 major and 2 minor criteria to be included. Major criteria: liver biopsy
showing alcoholic hepatitis (with or without Mallory bodies), hepatic encephalopathy,
azotaemia unexplained by another process (blood urea nitrogen > 20 mg% or creatinine
> 1.5 mg %), hyperbilirubinaemia (> 20 mg %) and prothrombin time prolonged >
4 seconds over control; and unresponsive to parenteral administration of vitamin K.
Minor criteria included fever not obviously secondary to another process, white blood
count > 12,000, hepatomegaly (span > 14 cm), splenomegaly, or liver stigmas (spider
telangiectasias, palmar erythema, ascites, oedema, etc.)
Positive hepatitis B antigen did not exclude them from the study if a percutaneous liver
biopsy confirmed alcoholic hepatitis
Exclusion criteria
AST > 500 IU/L; active gastrointestinal bleeding; pancreatitis; x-ray evidence of peptic
ulcer disease; active or questionably active tuberculosis; active infection; or severe psy-
chiatric disorder
Randomisation procedure
Predetermined code provided by the drug manufacturer
Number of participants randomised: 27
Prednisolone group: n = 12
Control group: n = 15
Interventions Prednisolone group: 6-methylprednisolone 80mg (equivalent to prednisolone 100 mg)
for 4-7 days; medication was then tapered on a flexible schedule with cessation of therapy
planned for 4 weeks unless death or complications
Control group: placebo
Additional interventions to the trial groups: both groups received comparable sup-
portive care required in hepatic decompensation. All participants with positive tuber-
culin tests were treated with isoniazid 300 mg daily and pyridoxine 50 mg daily
Duration of treatment: 5 weeks; participants were placed on treatment for 4-7 days.
Then the medication was tapered on flexible schedule with cessation of therapy planned
for 4 weeks unless death or complication intervened
Duration of follow-up: to hospital discharge
Outcomes Mortality
Liver histology
Adverse events
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Notes Letter sent to study authors in March 2000. No answer received
Quote: ”The patient was then randomised into a predetermined code provided by the
drugmanufacturer. (UpjohnCo., Kalamazoo,MI, prepared and supplied themedication
and placebo.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”The patient was then randomised
into a predetermined code provided by the
drug manufacturer. Immediately prior to
randomisation, patients were stratified into
two categories based on the presence or ab-
stinence of criteria permitting liver biopsy“
the purpose of this procedure was to pro-
vide comparable case material for both
steroid and placebo control groups.in the
absence of other contradictions, patients
with prothrombin times less than four sec-
onds prolonged were placed in the ”Biopsy
feasible“ group (n = 10)whether or not they
agreed to a biopsy. All other patients con-
stituted the ”Biopsy- Disallowed“ group (n
= 17).”
Allocation concealment (selection bias) Low risk Quote: “The patient was then randomised
into a predetermined code provided by the
drug manufacturer.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Quote: “80mg of 6-methylprednisolone or
equivalent number of placebo tablets (or
parenteral therapy of the same dosage in-
travenously if gastrointestinal function pre-
cluded oral intake.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Clinical evaluation was carried out
by junior staff physicians blinded to treat-
ment status of the patients.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3.7 %
Quote: “a steroid treated patient voluntar-
ily withdrew from the study after eight days
but was retained for statistical purposes.”
Prednisolone group: 1/12; control group:
0/15
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Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
related mortality were reported
Other bias Low risk None suspected
Theodossi 1982
Methods Randomised controlled trial
Country: UK
Intention-to-treat analysis: no
Sample size calculation: not reported
Participants Demographic characteristics
Age: not mentioned
Sex: prednisolone group: 19 men/8 women; control group: 12 men/16 women
Inclusion criteria and degree of severity
Patients had to satisfy the following criteria: history of alcohol intake ≥ 80 g/day for ≥
5 years; serum bilirubin > 80 pmol/L (normal up to 20 µmol/L); serum AST level ≥ 2
× upper limit of normal (normal up to 40 IU/L); prothrombin time prolonged by ≥ 9
seconds. Gastrointestinal bleeding, renal failure, and sepsis did not invalidate entry
Exclusion criteria
Hepatoma and other diseases such as recent myocardial infarction, accompanying cere-
brovascular accident including evidence of subdural haematoma, and active tuberculosis
Randomisation procedure
Random sealed envelope
Number of participants: 60 (55 analysed). Referred from other hospitals because of
the severity of their illness. 5 excluded from the analyses because of doubts in initial
diagnosis
Prednisolone group: n = 28 (analysed n = 27)
Control group: n = 32 (analysed n = 28)
Interventions Prednisolone group: intravenous methylprednisolone 1 g daily (equivalent to 1.25 g
prednisolone) for 3 days
Control group: no intervention
Additional treatment: participants who were too ill to take the standard hospital diet
received a ≥ 2000 calories as intravenous 20% glucose. Encephalopathy treated with
protein restriction (maximum of 20 g/day), lactulose (15-30 mL twice daily), and daily
magnesium sulphate enemas
Duration of treatment: 3 days
Durationof follow-up: little difference between groups inmean length of stay in hospital
(prednisolone group: 24.2 days; control group: 28.1 days)
Outcomes Mortality
Liver biochemistry
Adverse events
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Notes Letter sent to study authors in March 2000. No answer received
Quote: “Of the 60 patients who satisfied the entry criteria, one in the treatment group
and four in the control group were excluded from the final analysis because subsequent
findings in four cases cast doubt on the initial diagnosis, and one patient was later found
to have been given corticosteroids at the referring hospital. Thus there were 27 patients
in the treatment and 28 in the control group.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients … referred from other
hospitals because of the severity of their
illness. Patients were allocated by random
sealed envelope technique to a control or
treatment group …”
Allocation concealment (selection bias) Low risk Quote: “Patients were allocated by random
sealed envelope technique to a control or
treatment group, …”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Quote: “Patients were allocated by random
sealed envelope technique to a control or
treatment group, the latter receiving intra-
venous methylprednisolone 1 g daily for
three days.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk 8%
Quote: “Of the 60 patients who satisfied
the entry criteria, one in the treatment
group and four in the control group were
excluded from the final analysis because
subsequent findings in four cases cast doubt
on the initial diagnosis, and one patient
was later found to have been given corti-
costeroids at the referring hospital. Thus,
there were 27 patients in the treatment and
28 in the control group.”
Prednisolone group: 1/28; control group:
4/32
Selective reporting (reporting bias) Low risk No protocol available. However, all-cause
mortality, serious adverse events, and liver-
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related mortality were reported
Other bias Low risk None suspected
Thursz 2015
Methods Multicentre, randomised trial with a 2 × 2 factorial design (09/MRE09/59)
Country: UK (65 hospitals)
Dates: January 2011 to February 2014
Intention-to-treat analysis: yes
Sample size calculation: reported
Participants Demographic characteristics
Age (mean): prednisolone plus placebo (n = 274) 49.3 ± 10.6); prednisolone plus pen-
toxifylline (n = 277) 48.6 ± 9.8; control group: placebo plus pentoxifylline (276) 47.9 ±
10.2; placebo plus placebo (276) 48.8 ± 10.3
Sex: glucocorticosteroid groups: 359 (65.6%) men; control groups: 326 (59.8%) men
Hepatic encephalopathy: glucocorticosteroid groups: 152 (28%); control groups: 143
(26%)
Inclusion criteria and degree of severity
People abusing alcohol with a clinical diagnosis of severe alcoholic hepatitis manifested
by hepatomegaly, leukocytosis, serum bilirubin > 5 mg/dL, spontaneous hepatic en-
cephalopathy; aged ≥ 18 years; clinical diagnosis of alcoholic hepatitis; mean alcohol
consumption > 80 g/day for men and > 60 g/day for women; serum bilirubin > 80µmol/
L (4.7 mg/dL); discriminant function ≥ 32
Exclusion criteria
Jaundice for > 3 months; cessation of alcohol consumption for > 2 months before
randomisation; presence of other causes of liver disease; serum AST > 500 IU/L or serum
ALT > 300 IU/L; previous entry into the study within the preceding 6 months
Randomisation procedure
Web-based computer system
Number of participants randomised: 1103; data from 1053 were available for the
primary end-point analysis
Interventions Participants randomised to 1 of 4 groups: pentoxifylline-matched placebo + pred-
nisolone-matched placebo; pentoxifylline-matched placebo + prednisolone; pentoxi-
fylline + prednisolone-matched placebo; or pentoxifylline + prednisolone
Experimental groups: group 2 received prednisolone 40 mg daily + pentoxifylline-
matched placebo (n = 277); group 4 received prednisolone 40 mg daily + pentoxifylline
400 mg 3 times daily (n = 274)
Control groups: group 1 received pentoxifylline-matched placebo + prednisolone-
matched placebo (n = 276); group 3 received pentoxifylline 400 mg 3 times daily +
prednisolone matched placebo (n = 276)
Additional interventions to the trial groups: standard supportive care and nutritional
support. Clinician made decision regarding other treatments, such as terlipressin for
people with developing hepatorenal failure, acid suppression for prophylaxis against
gastrointestinal haemorrhage, antibiotics, and vitamin supplementation. People with
renal failure (defined as creatinine level > 500 µmol/L (> 5.7 mg/dL) or requirement
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for renal-replacement therapy), active gastrointestinal bleeding, or untreated sepsis, and
people requiring inotropic support with adrenaline or noradrenaline, were excluded
unless the condition stabilised within the first 7 days after admission to hospital
Duration of treatment: 28 days
Duration of follow-up: 1 year
Outcomes Mortality
Adverse events
Quality of life (using the EQ-5D score registered to Eudra CT 2009-013897-42 and
ISRCTN 88782125)
Notes EuropeanQuality of Life - 5Dimension - 5Level Scale (EQ-5D-5L): self-report,multiple
choice questionnaire that provides a simple descriptive profile and a single index value
for health status. Essentially consists of 2 pages: the EQ-5D descriptive system (page 2)
and the EQ VAS (page 3). The descriptive system comprises: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no
problems, slight problems, moderate problems, severe problems, and extreme problems.
The EQ VAS records the respondent’s self-rated health on a vertical, VAS. The EQ-5D-
5L takes a few minutes to complete
A summary index with a maximum score of 1 can be derived from these 5 dimensions
by conversion with a table of scores. The maximum score of 1 indicates the best health
state, by contrast with the scores of individual questions, where higher scores indicate
more severe or frequent problems. In addition, there is a VAS to indicate the general
health status with 100 indicating the best health status
Study approved by the Multicenter Research Ethics Committee (reference number 09/
MRE09/59), and clinical trial authorisation received from theMedicines and Healthcare
Products Regulatory Agency (funded by the National Institute for Health Research
Health Technology Assessment program; STOPAH EudraCT number, 2009-013897-
42, and Current Controlled Trials number, ISRCTN88782125
Trial was conducted and reported according to the protocol, the Medicines for Human
Use (Clinical Trials) Regulations 2004, as amended in2006, the EuropeanUnionClinical
Trials Directive (Directive 2001/20/EC) guidelines, the principles of the International
Conference on Harmonisation Good Clinical Practice under the oversight of University
Hospital Southampton NHS Foundation Trust, and the provisions of the Declaration
of Helsinki
Letter sent to M Thursz 12 October 2016. No reply received yet
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “… A web-based computer sys-
tem (Tenalea, Forms-Vision) was used to
enrol eligible patients and randomly as-
sign them to study groups. The random-
ization schedule was created with the use
of Stata software, version 11 (StataCorp)
. Randomization was performed with a
block size of four, with stratification accord-
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ing to geographic area and risk category.
The high-risk category consisted of patients
who had an occurrence of gastrointestinal
bleeding, renal impairment, or sepsis be-
fore randomisation. All other patients were
assigned to the intermediate-risk category.
”
Allocation concealment (selection bias) Low risk Quote: “The randomization schedule was
created with the use of Stata software, ver-
sion 11 (StataCorp). Randomization was
performed with a block size of four, with
stratification according to geographic area
and risk category. Treatment allocation was
blinded to site staff and the patient by pro-
viding each patientwith a unique four-digit
patient pack number.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Quote: “The treatment arm was also con-
cealed to investigators and researchers.
Only the study statisticians were unblinded
and this was for analysis purposes only.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “An independent data monitor-
ing and ethics committee, whose members
were aware of the group assignments, was
convened to review the conduct of the trial
and to analyze primary end-point data, us-
ing prespecified stopping guidelines, after
the recruitment of 200, 400, and 800 pa-
tients, to avoid continued recruitment in
the event that a definitive result had been
achieved. Data collected by site investiga-
tive teamswere submitted to the clinical tri-
als unit and analysed by study statisticians.
The first author wrote the first draft of the
manuscript, with substantial contributions
from the coauthors. All the authors vouch
for the accuracy and completeness of the
data and analyses.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data at the specific time points
were reported.
Quote: “At the time the trial was stopped,
33 patients who underwent randomiza-
tion during the last 90 days of the trial
could not be included in the 90-day or
12-month analyses. In addition, there were
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159 patients who underwent randomiza-
tionwithin 90days to 12months before the
end of trial who could not be included in
12-month analyses. The four groups were
well matched with regard to their baseline
characteristics, including laboratory values
(See Table 1 in the published article). At
28 days, 16% of the patients had died, 1%
had been lost to follow-up, and 2% had
withdrawn from the study. At 90 days, 29%
of the patients (285 of 968 patients) had
died, 5% had been lost to follow-up, 3%
hadwithdrawn, and4%hadnot completed
follow-up owing to cessation of the study.
At 1 year, 56% of the patients (421 of 747
patients) had died or undergone liver trans-
plantation (the latter were 3 patients), 8%
had been lost to follow-up, 4% had with-
drawn, and 20% had not completed fol-
low-up owing to cessation of the study due
to limitations on funding.”
Quote: “Owing to limitations on funding,
the trial was stopped after all enrolled pa-
tients had completed at least 28 days of fol-
low-up.”
Quote: “This project was funded by the
National Institute for Health Research
(NIHR) Health Technology Assessment
programme. The NIHR Clinical Research
Network provided research nurse support
and the Imperial College Biomedical Re-
search Centre also provided funding.”
Selective reporting (reporting bias) Low risk Protocol was available, and data on all pro-
tocol outcomes such as all-cause mortality,
serious adverse events, liver-related mortal-
ity, and quality of life were reported
Other bias Low risk None suspected
ALT: alanine aminotransferase; AST: aspartate aminotransferase; EQ-5D: European Quality of Life-5 dimensions; GAHS: Glasgow
alcoholic hepatitis score; MDF: Maddrey’s Discriminant Function; MELD: model for end-stage liver disease; n: number of partici-
pants; PPD: purified protein derivative; SD: standard deviation; VAS: visual analogue scale.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alvarez 2004 Observational study (patient series). 13 participants with severe alcoholic hepatitis treated with systemic gluco-
corticosteroids and total enteral nutrition
Cabré 2000 Randomised trial of glucocorticosteroids versus nutrition in people with alcoholic hepatitis. Participants received
oral or intravenous prednisolone or enteral nutrition (2000 kcal/day of a chemically defined polymeric enteral
diet enriched in branched-chain amino acids)
Christensen 1981 Quasi-randomised clinical study
Copenhagen 1969 Meta-analysis
Daures 1991 Meta-analysis
Dhanda 2016 Prospective single-centre cohort of people with severe alcoholic hepatitis treated with steroids; incidence and
significance of infection
Galambos 1984 Reported in article through private contacts as part of Shumaker 1978.
Gill 1984 Trial randomised 10 people with severe alcoholic hepatitis to prednisolone, testosterone, and amino acid sup-
plement versus no intervention
Goldis 2000 Observational study (patient series); the authors used a control group from the same centre
Hozo 1996 Trial randomised people with alcoholic liver cirrhosis to glucocorticosteroids versus placebo
Imperiale 1990 Meta-analysis
Lee 2016 Review
Lesesne 1978 Randomised trial of glucocorticosteroids versus nutrition in people with alcoholic hepatitis. Participants received
glucocorticosteroids plus permission to eat as theywanted or amaximum of 600 kcal/day as intravenous glucose,
while the control group received caloric supplements of at least 1600 kcal/day
Mal 1991 Abstract about influence of corticosteroids on the level of serum tumour necrosis factor concentrations
Mathurin 2018 Trial randomised people with alcoholic hepatitis to receive selonsertib 18 mg versus placebo infliximab versus
placebo. All participants received prednisone 40 mg orally
Mendenhall 1993 Chapter on alcoholic hepatitis in a book
Moreno 2014 Multicentral study with 2 groups of comparison of intensive enteral nutrition with complete nutrition. Both
groups received prednisolone
Morris 2005 Observational study (patient series)
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Naganuma 2014 Trial of granulocytapheresis and leukocytapheresis for the treatment of severe alcoholic hepatitis
Naveau 2004 Trial randomised people with alcoholic hepatitis to receive infliximab versus placebo. All participants received
prednisone
Phillips 2001 Trial randomised participants to antioxidants versus glucocorticosteroids
Poynard 1991 Meta-analysis on alcoholic hepatitis
Reynolds 1989 Narrative review on alcoholic hepatitis
Schlichting 1976 Quasi-randomised clinical study
Singal 2018 Review
Spahr 2002 Trial randomised people with alcoholic hepatitis to receive infliximab versus placebo. All participants received
prednisone
Stewart 2002 Trial stratified participants by gender and glucocorticosteroid use, and then randomised participants to receive
antioxidants versus placebo
Szabo 2018 Trial randomised people with alcoholic hepatitis to receive prednisolone 32 mg orally daily for 28 days versus a
combination of anakinra + pentoxifylline + zinc orally
Tygstrup 1979 Meta-analysis
Characteristics of ongoing studies [ordered by study ID]
NCT03160651
Trial name or title Corticosteroids in severe alcoholic hepatitis patients with early spontaneous improvement
Methods Interventional (clinical trial). Double-blind randomised trial: Investigator, participants, and care providers
will be masked. Only statisticians and pharmacist will not be masked
Participants Participants with alcoholic hepatitis: aged ≥ 18 years of either sex
Inclusion criteria: clinical syndrome of alcoholic hepatitis; recent jaundice or in recent aggravation (<3months)
, serum bilirubin > 5 mg/dL, history of excess alcohol abuse (> 40 g/day); alcoholic hepatitis confirmed by
liver biopsy (histological criteria of alcoholic hepatitis defined according to EASL clinical practice guidelines:
steatosis, hepatocyte ballooning, and an inflammatory infiltrate with PMNs); spontaneous liver function
improvement, defined by a decrease in Maddrey Discriminant Function and serum bilirubin > 10% between
admission and day 7 after admission
< 2weeks since admission to hospital;MaddreyDiscriminant Function≥ 32; peoplemust voluntarily sign and
date an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee
prior to the initiation of any screening or study-specific procedures; be able to understand and adhere to the
study visit schedule and all other protocol requirements; people with significant hepatic encephalopathy will
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not be excluded. In this case, the person should be accompanied by a legal representative who will decide
participation in the clinical study and sign informed consent form
Exclusion criteria: other causes of liver disease including viral hepatitis (positive hepatitis B surface antigen,
HCVRNA positive), autoimmune hepatitis, biliary obstruction; other disease compromising 90-day survival;
positive HIV serology; uncontrolled infection. All participants will be screened for infection involving chest
radiography, urinalysis, PMNs count in ascites (if ascites present). All other sign or clinical suspicion of
infection with or without antibiotherapy will be recorded as an infection. Positive culture and initiation of
antibiotics with clinical or radiological signs of infection, as well as clinical suspicion, will be recorded as
infection. People with evidence of sepsis will be treated for a minimum of 2 days with appropriate antibiotics.
Once the local principal investigator considers that the sepsis is under control, the person may be rescreened
and randomised. Uncontrolled gastrointestinal bleeding judged as controlled for≥ 5 days; serum creatinine >
2.5 mg/dL, under renal replacement therapy or under terlipressin (or other vasoactive drugs); pentoxyphilline
therapy; pregnant or lactating women
Interventions Parallel assignment of methylprednisolone or placebo
Active comparator: methylprednisolone: methylprednisolone 32 mg/day for 28 days
Placebo comparator: matching placebo for 28 days
Outcomes Primary outcomes
Mortality at 90 days
Secondary outcome
Mortality at 28 days
Incidence of infections during the study period (90 days)
Starting date Estimated study start date: June 2017
Contact information Contact: Christophe Moreno, MD, PhD +32 2 5553714christophe.moreno@erasme.ulb.ac.be
Contact: Françoise Smits, Nurse +32 2 5554478francoise.smits@erasme.ulb.ac.be
Sponsors and collaborators: Erasme University Hospital
Principal investigator: Christophe Moreno, MD, PhD; Erasme University Hospital
Notes Estimated primary completion date: June 2020
Estimated study completion date: January 2021
EASL: European Association for the Study of the Liver; HCV: hepatitis C virus; MDF: Maddrey’s Discriminant Function; PMN:
polymorphonuclear neutrophil.
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D A T A A N D A N A L Y S E S
Comparison 1. Glucocorticosteroids versus placebo/no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Up to 3 months’ follow-
up after randomisation
15 1861 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.70, 1.15]
1.2 At the end of treatment 14 1824 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.66, 1.15]
1.3 At 1 year after
randomisation
3 1343 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.91, 1.17]
2 Health-related quality of life 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Up to 3 months 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Up to 1 year 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Serious adverse events during
treatment
15 1861 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.85, 1.29]
4 Liver-related mortality: up to
3 months’ follow-up after
randomisation
15 1861 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.69, 1.14]
5 Participants with any
complication up to 3 months’
follow-up
15 1861 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.86, 1.27]
6 Participants with non-serious
adverse events up to 3 months’
follow-up after randomisation
4 160 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.72, 5.48]
Comparison 2. Subgroup analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Bias risk 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Trials at low risk 1 1103 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.84, 1.26]
1.2 Trials at high risk 14 758 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.63, 1.17]
2 Trials without for-profit funding
compared to trials at risk of
for-profit funding
15 1861 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.70, 1.15]
2.1 Trials without for-profit
funding
1 1103 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.84, 1.26]
2.2 Trials at risk of for-profit
funding
14 758 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.63, 1.17]
3 Severity of alcoholic hepatitis 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Mild alcoholic hepatitis 4 182 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.58, 1.80]
3.2 Severe alcoholic hepatitis 14 1679 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.16]
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4 Glucocorticosteroid
(prednisolone) dose
15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 ≤ 40 mg 10 1547 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.50, 1.14]
4.2 > 40 mg 5 314 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.79, 1.30]
5 Alcoholic hepatitis without or
with cirrhosis
15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Without cirrhosis 3 123 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.18, 3.48]
5.2 With cirrhosis 12 1738 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.74, 1.16]
6 Alcoholic hepatitis without or
with hepatorenal syndrome
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 With hepatorenal
syndrome
8 1382 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.85, 1.17]
6.2 Without hepatorenal
syndrome
2 129 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.05, 6.49]
7 Alcoholic hepatitis without or
with ascites
14 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 With ascites 13 729 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.60, 1.12]
7.2 Unclear if they had ascites 1 29 Risk Ratio (M-H, Random, 95% CI) 2.83 [0.61, 13.06]
Comparison 3. Sensitivity analysis: all-cause mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Best-worst scenario all-cause
mortality up to 3 months’
follow-up after randomisation
15 1861 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.64, 1.05]
2 Worst-best scenario analysis:
all-cause mortality up to
3 months’ follow-up after
randomisation
15 1861 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [1.06, 1.37]
Comparison 4. Sensitivity analysis: serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Best-worse scenario of serious
adverse events during treatment
15 1861 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.83, 1.21]
2 Worst-best scenario of serious
adverse events during treatment
15 1861 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.05, 1.31]
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Analysis 1.1. Comparison 1 Glucocorticosteroids versus placebo/no intervention, Outcome 1 All-cause
mortality.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 1 Glucocorticosteroids versus placebo/no intervention
Outcome: 1 All-cause mortality
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Up to 3 months’ follow-up after randomisation
Blitzer 1977 8/17 5/16 5.6 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 5/21 3.6 % 0.70 [ 0.22, 2.27 ]
Campra 1973 7/22 10/28 6.5 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 2/36 11/31 2.6 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 5/31 4.8 % 1.80 [ 0.68, 4.76 ]
Depew 1980 8/15 7/13 7.7 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/20 6/17 1.4 % 0.14 [ 0.02, 1.06 ]
Maddrey 1978 3/25 6/32 3.1 % 0.64 [ 0.18, 2.31 ]
Mendenhall 1977 4/12 2/17 2.3 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 34/90 35/88 13.6 % 0.95 [ 0.66, 1.37 ]
Porter 1971 6/11 7/9 8.4 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 4.8 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 6/12 7/15 6.6 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 16/32 11.7 % 1.21 [ 0.77, 1.92 ]
Thursz 2015 145/551 141/552 17.4 % 1.03 [ 0.84, 1.26 ]
Subtotal (95% CI) 927 934 100.0 % 0.90 [ 0.70, 1.15 ]
Total events: 258 (Glucocorticosteroids), 279 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.08; Chi2 = 25.23, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 0.85 (P = 0.40)
2 At the end of treatment
Blitzer 1977 4/17 2/16 2.7 % 1.88 [ 0.40, 8.90 ]
Bories 1987 1/24 2/21 1.3 % 0.44 [ 0.04, 4.49 ]
Campra 1973 7/22 10/28 7.7 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 2/36 11/31 3.2 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 5/31 5.8 % 1.80 [ 0.68, 4.76 ]
0.02 0.1 1 10 50
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(Continued . . . )
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Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Depew 1980 8/15 7/13 9.0 % 0.99 [ 0.50, 1.98 ]
Maddrey 1978 3/25 6/32 3.8 % 0.64 [ 0.18, 2.31 ]
Mendenhall 1977 4/12 2/17 2.8 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 18/90 16/88 10.3 % 1.10 [ 0.60, 2.02 ]
Porter 1971 6/11 7/9 9.7 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 5.7 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 6/12 7/15 7.8 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 16/32 13.1 % 1.21 [ 0.77, 1.92 ]
Thursz 2015 73/551 95/552 16.9 % 0.77 [ 0.58, 1.02 ]
Subtotal (95% CI) 907 917 100.0 % 0.87 [ 0.66, 1.15 ]
Total events: 162 (Glucocorticosteroids), 202 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.10; Chi2 = 22.61, df = 13 (P = 0.05); I2 =42%
Test for overall effect: Z = 0.95 (P = 0.34)
3 At 1 year after randomisation
De 2014 10/31 6/31 2.1 % 1.67 [ 0.69, 4.02 ]
Mendenhall 1984 55/90 50/88 26.6 % 1.08 [ 0.84, 1.38 ]
Thursz 2015 211/551 211/552 71.4 % 1.00 [ 0.86, 1.16 ]
Subtotal (95% CI) 672 671 100.0 % 1.03 [ 0.91, 1.17 ]
Total events: 276 (Glucocorticosteroids), 267 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.40, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
0.02 0.1 1 10 50
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Analysis 1.2. Comparison 1 Glucocorticosteroids versus placebo/no intervention, Outcome 2 Health-
related quality of life.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 1 Glucocorticosteroids versus placebo/no intervention
Outcome: 2 Health-related quality of life
Study or subgroup Glucocorticosteroids
Placebo/no
intervention
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Up to 3 months
Thursz 2015 191 0.553 (0.358) 186 0.59 (0.353) -0.04 [ -0.11, 0.03 ]
2 Up to 1 year
Thursz 2015 88 0.583 (0.356) 82 0.59 (0.338) 0.00 [ -0.11, 0.10 ]
-2 -1 0 1 2
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Analysis 1.3. Comparison 1 Glucocorticosteroids versus placebo/no intervention, Outcome 3 Serious
adverse events during treatment.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 1 Glucocorticosteroids versus placebo/no intervention
Outcome: 3 Serious adverse events during treatment
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blitzer 1977 8/17 5/16 4.5 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 2/21 1.6 % 1.75 [ 0.36, 8.61 ]
Campra 1973 7/22 10/28 5.4 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 5/36 12/31 4.1 % 0.36 [ 0.14, 0.91 ]
De 2014 9/31 6/31 4.3 % 1.50 [ 0.61, 3.71 ]
Depew 1980 11/15 8/13 9.4 % 1.19 [ 0.70, 2.02 ]
Helman 1971 9/20 6/17 5.2 % 1.28 [ 0.57, 2.85 ]
Maddrey 1978 4/25 6/32 2.9 % 0.85 [ 0.27, 2.70 ]
Mendenhall 1977 4/12 2/17 1.7 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 18/90 16/88 7.9 % 1.10 [ 0.60, 2.02 ]
Porter 1971 6/11 7/9 7.3 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 3.8 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 8/12 9/15 8.4 % 1.11 [ 0.63, 1.97 ]
Theodossi 1982 20/28 16/32 12.1 % 1.43 [ 0.94, 2.17 ]
Thursz 2015 244/551 217/552 21.6 % 1.13 [ 0.98, 1.30 ]
Total (95% CI) 927 934 100.0 % 1.05 [ 0.85, 1.29 ]
Total events: 361 (Glucocorticosteroids), 338 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.05; Chi2 = 21.82, df = 14 (P = 0.08); I2 =36%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours gluco Favours plac/no inter
83Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Glucocorticosteroids versus placebo/no intervention, Outcome 4 Liver-related
mortality: up to 3 months’ follow-up after randomisation.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 1 Glucocorticosteroids versus placebo/no intervention
Outcome: 4 Liver-related mortality: up to 3 months’ follow-up after randomisation
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Helman 1971 1/20 6/17 1.4 % 0.14 [ 0.02, 1.06 ]
Porter 1971 6/11 7/9 8.5 % 0.70 [ 0.37, 1.33 ]
Campra 1973 7/22 10/28 6.6 % 0.89 [ 0.41, 1.96 ]
Blitzer 1977 8/17 5/16 5.6 % 1.51 [ 0.62, 3.65 ]
Mendenhall 1977 4/12 2/17 2.3 % 2.83 [ 0.61, 13.06 ]
Shumaker 1978 6/12 7/15 6.7 % 1.07 [ 0.49, 2.34 ]
Maddrey 1978 3/25 6/32 3.2 % 0.64 [ 0.18, 2.31 ]
Depew 1980 8/15 7/13 7.8 % 0.99 [ 0.50, 1.98 ]
Theodossi 1982 17/28 16/32 11.7 % 1.21 [ 0.77, 1.92 ]
Mendenhall 1984 34/90 35/88 13.6 % 0.95 [ 0.66, 1.37 ]
Bories 1987 3/24 5/21 3.1 % 0.53 [ 0.14, 1.94 ]
Carithers 1989 2/36 11/31 2.6 % 0.16 [ 0.04, 0.65 ]
Ramond 1992 4/33 16/32 4.8 % 0.24 [ 0.09, 0.65 ]
Thursz 2015 145/551 141/552 17.1 % 1.03 [ 0.84, 1.26 ]
De 2014 9/31 5/31 4.9 % 1.80 [ 0.68, 4.76 ]
Total (95% CI) 927 934 100.0 % 0.89 [ 0.69, 1.14 ]
Total events: 257 (Glucocorticosteroids), 279 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.08; Chi2 = 25.81, df = 14 (P = 0.03); I2 =46%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Glucocorticosteroids versus placebo/no intervention, Outcome 5 Participants
with any complication up to 3 months’ follow-up.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 1 Glucocorticosteroids versus placebo/no intervention
Outcome: 5 Participants with any complication up to 3 months’ follow-up
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blitzer 1977 10/17 5/16 4.4 % 1.88 [ 0.82, 4.31 ]
Bories 1987 4/24 5/21 2.4 % 0.70 [ 0.22, 2.27 ]
Campra 1973 8/22 10/28 5.2 % 1.02 [ 0.48, 2.14 ]
Carithers 1989 5/36 12/31 3.7 % 0.36 [ 0.14, 0.91 ]
De 2014 10/31 8/31 4.8 % 1.25 [ 0.57, 2.74 ]
Depew 1980 13/15 8/13 9.4 % 1.41 [ 0.88, 2.26 ]
Helman 1971 9/20 8/17 5.7 % 0.96 [ 0.48, 1.92 ]
Maddrey 1978 7/25 7/32 3.8 % 1.28 [ 0.52, 3.17 ]
Mendenhall 1977 4/12 2/17 1.5 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 34/90 35/88 12.0 % 0.95 [ 0.66, 1.37 ]
Porter 1971 6/11 7/9 6.4 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 3.3 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 8/12 9/15 7.4 % 1.11 [ 0.63, 1.97 ]
Theodossi 1982 20/28 16/32 10.7 % 1.43 [ 0.94, 2.17 ]
Thursz 2015 298/551 266/552 19.5 % 1.12 [ 1.00, 1.26 ]
Total (95% CI) 927 934 100.0 % 1.04 [ 0.86, 1.27 ]
Total events: 440 (Glucocorticosteroids), 414 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.05; Chi2 = 24.29, df = 14 (P = 0.04); I2 =42%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Glucocorticosteroids versus placebo/no intervention, Outcome 6 Participants
with non-serious adverse events up to 3 months’ follow-up after randomisation.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 1 Glucocorticosteroids versus placebo/no intervention
Outcome: 6 Participants with non-serious adverse events up to 3 months’ follow-up after randomisation
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blitzer 1977 2/17 0/16 9.9 % 4.72 [ 0.24, 91.41 ]
De 2014 1/31 2/31 38.4 % 0.50 [ 0.05, 5.23 ]
Depew 1980 2/15 0/13 10.2 % 4.38 [ 0.23, 83.62 ]
Helman 1971 5/20 2/17 41.5 % 2.13 [ 0.47, 9.59 ]
Total (95% CI) 83 77 100.0 % 1.99 [ 0.72, 5.48 ]
Total events: 10 (Glucocorticosteroids), 4 (Placebo/no intervention)
Heterogeneity: Chi2 = 1.94, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after
randomisation, Outcome 1 Bias risk.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Outcome: 1 Bias risk
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Trials at low risk
Thursz 2015 145/551 141/552 100.0 % 1.03 [ 0.84, 1.26 ]
Subtotal (95% CI) 551 552 100.0 % 1.03 [ 0.84, 1.26 ]
Total events: 145 (Glucocorticosteroids), 141 (Placebo/no intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
2 Trials at high risk
Blitzer 1977 8/17 5/16 7.2 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 5/21 4.9 % 0.70 [ 0.22, 2.27 ]
Campra 1973 7/22 10/28 8.1 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 2/36 11/31 3.7 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 5/31 6.4 % 1.80 [ 0.68, 4.76 ]
Depew 1980 8/15 7/13 9.3 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/20 6/17 2.1 % 0.14 [ 0.02, 1.06 ]
Maddrey 1978 3/25 6/32 4.3 % 0.64 [ 0.18, 2.31 ]
Mendenhall 1977 4/12 2/17 3.3 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 34/90 35/88 13.8 % 0.95 [ 0.66, 1.37 ]
Porter 1971 6/11 7/9 9.9 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 6.3 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 6/12 7/15 8.2 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 16/32 12.5 % 1.21 [ 0.77, 1.92 ]
Subtotal (95% CI) 376 382 100.0 % 0.86 [ 0.63, 1.17 ]
Total events: 113 (Glucocorticosteroids), 138 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.14; Chi2 = 25.22, df = 13 (P = 0.02); I2 =48%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
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Analysis 2.2. Comparison 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after
randomisation, Outcome 2 Trials without for-profit funding compared to trials at risk of for-profit funding.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Outcome: 2 Trials without for-profit funding compared to trials at risk of for-profit funding
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Trials without for-profit funding
Thursz 2015 145/551 141/552 17.4 % 1.03 [ 0.84, 1.26 ]
Subtotal (95% CI) 551 552 17.4 % 1.03 [ 0.84, 1.26 ]
Total events: 145 (Glucocorticosteroids), 141 (Placebo/no intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
2 Trials at risk of for-profit funding
Blitzer 1977 8/17 5/16 5.6 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 5/21 3.6 % 0.70 [ 0.22, 2.27 ]
Campra 1973 7/22 10/28 6.5 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 2/36 11/31 2.6 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 5/31 4.8 % 1.80 [ 0.68, 4.76 ]
Depew 1980 8/15 7/13 7.7 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/20 6/17 1.4 % 0.14 [ 0.02, 1.06 ]
Maddrey 1978 3/25 6/32 3.1 % 0.64 [ 0.18, 2.31 ]
Mendenhall 1977 4/12 2/17 2.3 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 34/90 35/88 13.6 % 0.95 [ 0.66, 1.37 ]
Porter 1971 6/11 7/9 8.4 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 4.8 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 6/12 7/15 6.6 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 16/32 11.7 % 1.21 [ 0.77, 1.92 ]
Subtotal (95% CI) 376 382 82.6 % 0.86 [ 0.63, 1.17 ]
Total events: 113 (Glucocorticosteroids), 138 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.14; Chi2 = 25.22, df = 13 (P = 0.02); I2 =48%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 927 934 100.0 % 0.90 [ 0.70, 1.15 ]
Total events: 258 (Glucocorticosteroids), 279 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.08; Chi2 = 25.23, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
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Analysis 2.3. Comparison 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after
randomisation, Outcome 3 Severity of alcoholic hepatitis.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Outcome: 3 Severity of alcoholic hepatitis
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mild alcoholic hepatitis
Bories 1987 4/24 5/21 23.5 % 0.70 [ 0.22, 2.27 ]
Helman 1971 0/11 0/11 Not estimable
Maddrey 1978 0/11 0/13 Not estimable
Mendenhall 1984 14/46 12/45 76.5 % 1.14 [ 0.59, 2.19 ]
Subtotal (95% CI) 92 90 100.0 % 1.02 [ 0.58, 1.80 ]
Total events: 18 (Glucocorticosteroids), 17 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
2 Severe alcoholic hepatitis
Blitzer 1977 8/17 5/16 5.5 % 1.51 [ 0.62, 3.65 ]
Campra 1973 5/22 10/28 5.2 % 0.64 [ 0.25, 1.59 ]
Carithers 1989 2/36 11/31 2.5 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 5/31 4.8 % 1.80 [ 0.68, 4.76 ]
Depew 1980 8/15 7/13 7.9 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/9 6/6 2.3 % 0.16 [ 0.04, 0.72 ]
Maddrey 1978 3/14 6/19 3.4 % 0.68 [ 0.20, 2.26 ]
Mendenhall 1977 4/12 2/17 2.2 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 20/44 23/43 13.6 % 0.85 [ 0.55, 1.30 ]
Porter 1971 6/11 7/9 8.7 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 6/32 3.5 % 0.65 [ 0.20, 2.08 ]
Shumaker 1978 6/12 7/15 6.7 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 16/32 12.8 % 1.21 [ 0.77, 1.92 ]
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(. . . Continued)
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Thursz 2015 145/551 141/552 20.8 % 1.03 [ 0.84, 1.26 ]
Subtotal (95% CI) 835 844 100.0 % 0.92 [ 0.73, 1.16 ]
Total events: 238 (Glucocorticosteroids), 252 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.06; Chi2 = 20.61, df = 13 (P = 0.08); I2 =37%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 2.4. Comparison 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after
randomisation, Outcome 4 Glucocorticosteroid (prednisolone) dose.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Outcome: 4 Glucocorticosteroid (prednisolone) dose
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≤ 40 mg
Blitzer 1977 8/17 5/16 10.8 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 5/21 7.8 % 0.70 [ 0.22, 2.27 ]
Campra 1973 7/22 10/28 12.0 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 2/36 11/31 6.0 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 5/31 9.7 % 1.80 [ 0.68, 4.76 ]
Depew 1980 8/15 7/13 13.3 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/20 6/17 3.5 % 0.14 [ 0.02, 1.06 ]
Maddrey 1978 3/25 6/32 7.0 % 0.64 [ 0.18, 2.31 ]
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(. . . Continued)
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ramond 1992 4/33 16/32 9.7 % 0.24 [ 0.09, 0.65 ]
Thursz 2015 145/551 141/552 20.3 % 1.03 [ 0.84, 1.26 ]
Subtotal (95% CI) 774 773 100.0 % 0.75 [ 0.50, 1.14 ]
Total events: 191 (Glucocorticosteroids), 212 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.21; Chi2 = 21.40, df = 9 (P = 0.01); I2 =58%
Test for overall effect: Z = 1.34 (P = 0.18)
2 > 40 mg
Mendenhall 1977 4/12 2/17 2.6 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 34/90 35/88 44.2 % 0.95 [ 0.66, 1.37 ]
Porter 1971 6/11 7/9 14.6 % 0.70 [ 0.37, 1.33 ]
Shumaker 1978 6/12 7/15 9.8 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 16/32 28.8 % 1.21 [ 0.77, 1.92 ]
Subtotal (95% CI) 153 161 100.0 % 1.02 [ 0.79, 1.30 ]
Total events: 67 (Glucocorticosteroids), 67 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.77, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 1.48, df = 1 (P = 0.22), I2 =33%
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Analysis 2.5. Comparison 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after
randomisation, Outcome 5 Alcoholic hepatitis without or with cirrhosis.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Outcome: 5 Alcoholic hepatitis without or with cirrhosis
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Without cirrhosis
Carithers 1989 2/36 11/31 31.1 % 0.16 [ 0.04, 0.65 ]
Mendenhall 1977 4/12 2/17 29.9 % 2.83 [ 0.61, 13.06 ]
Shumaker 1978 6/12 7/15 39.0 % 1.07 [ 0.49, 2.34 ]
Subtotal (95% CI) 60 63 100.0 % 0.79 [ 0.18, 3.48 ]
Total events: 12 (Glucocorticosteroids), 20 (Placebo/no intervention)
Heterogeneity: Tau2 = 1.32; Chi2 = 8.78, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.32 (P = 0.75)
2 With cirrhosis
Blitzer 1977 8/17 5/16 5.4 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 5/21 3.3 % 0.70 [ 0.22, 2.27 ]
Campra 1973 7/22 10/28 6.5 % 0.89 [ 0.41, 1.96 ]
De 2014 9/31 5/31 4.6 % 1.80 [ 0.68, 4.76 ]
Depew 1980 8/15 7/13 8.0 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/20 6/17 1.2 % 0.14 [ 0.02, 1.06 ]
Maddrey 1978 3/25 6/32 2.9 % 0.64 [ 0.18, 2.31 ]
Mendenhall 1984 34/90 35/88 16.7 % 0.95 [ 0.66, 1.37 ]
Porter 1971 6/11 7/9 8.9 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 4.6 % 0.24 [ 0.09, 0.65 ]
Theodossi 1982 17/28 16/32 13.6 % 1.21 [ 0.77, 1.92 ]
Thursz 2015 145/551 141/552 24.3 % 1.03 [ 0.84, 1.26 ]
Subtotal (95% CI) 867 871 100.0 % 0.92 [ 0.74, 1.16 ]
Total events: 246 (Glucocorticosteroids), 259 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.05; Chi2 = 16.79, df = 11 (P = 0.11); I2 =35%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.83), I2 =0.0%
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Analysis 2.6. Comparison 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after
randomisation, Outcome 6 Alcoholic hepatitis without or with hepatorenal syndrome.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Outcome: 6 Alcoholic hepatitis without or with hepatorenal syndrome
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 With hepatorenal syndrome
Campra 1973 7/22 10/28 4.2 % 0.89 [ 0.41, 1.96 ]
Depew 1980 8/15 7/13 5.4 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/20 6/17 0.6 % 0.14 [ 0.02, 1.06 ]
Maddrey 1978 3/25 6/32 1.6 % 0.64 [ 0.18, 2.31 ]
Porter 1971 6/11 7/9 6.3 % 0.70 [ 0.37, 1.33 ]
Shumaker 1978 6/12 7/15 4.2 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 16/32 12.4 % 1.21 [ 0.77, 1.92 ]
Thursz 2015 145/551 141/552 65.2 % 1.03 [ 0.84, 1.26 ]
Subtotal (95% CI) 684 698 100.0 % 1.00 [ 0.85, 1.17 ]
Total events: 193 (Glucocorticosteroids), 200 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.17, df = 7 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Without hepatorenal syndrome
Carithers 1989 2/36 11/31 47.7 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 5/31 52.3 % 1.80 [ 0.68, 4.76 ]
Subtotal (95% CI) 67 62 100.0 % 0.56 [ 0.05, 6.49 ]
Total events: 11 (Glucocorticosteroids), 16 (Placebo/no intervention)
Heterogeneity: Tau2 = 2.74; Chi2 = 8.05, df = 1 (P = 0.005); I2 =88%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.64), I2 =0.0%
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Analysis 2.7. Comparison 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after
randomisation, Outcome 7 Alcoholic hepatitis without or with ascites.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 2 Subgroup analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Outcome: 7 Alcoholic hepatitis without or with ascites
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 With ascites
Blitzer 1977 8/17 5/16 7.4 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 5/21 5.0 % 0.70 [ 0.22, 2.27 ]
Campra 1973 7/22 10/28 8.4 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 2/36 11/31 3.8 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 5/31 6.5 % 1.80 [ 0.68, 4.76 ]
Depew 1980 8/15 7/13 9.6 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/20 6/17 2.1 % 0.14 [ 0.02, 1.06 ]
Maddrey 1978 3/25 6/32 4.4 % 0.64 [ 0.18, 2.31 ]
Mendenhall 1984 34/90 35/88 14.5 % 0.95 [ 0.66, 1.37 ]
Porter 1971 6/11 7/9 10.3 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 6.5 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 6/12 7/15 8.5 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 16/32 13.1 % 1.21 [ 0.77, 1.92 ]
Subtotal (95% CI) 364 365 100.0 % 0.82 [ 0.60, 1.12 ]
Total events: 109 (Glucocorticosteroids), 136 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.14; Chi2 = 23.29, df = 12 (P = 0.03); I2 =48%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Unclear if they had ascites
Mendenhall 1977 4/12 2/17 100.0 % 2.83 [ 0.61, 13.06 ]
Subtotal (95% CI) 12 17 100.0 % 2.83 [ 0.61, 13.06 ]
Total events: 4 (Glucocorticosteroids), 2 (Placebo/no intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Chi2 = 2.41, df = 1 (P = 0.12), I2 =59%
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Analysis 3.1. Comparison 3 Sensitivity analysis: all-cause mortality, Outcome 1 Best-worst scenario all-
cause mortality up to 3 months’ follow-up after randomisation.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 3 Sensitivity analysis: all-cause mortality
Outcome: 1 Best-worst scenario all-cause mortality up to 3 months’ follow-up after randomisation
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blitzer 1977 8/17 5/16 5.4 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 5/21 3.5 % 0.70 [ 0.22, 2.27 ]
Campra 1973 7/22 10/28 6.4 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 2/36 11/31 2.5 % 0.16 [ 0.04, 0.65 ]
De 2014 9/31 6/31 5.3 % 1.50 [ 0.61, 3.71 ]
Depew 1980 8/15 7/13 7.6 % 0.99 [ 0.50, 1.98 ]
Helman 1971 1/20 6/17 1.4 % 0.14 [ 0.02, 1.06 ]
Maddrey 1978 3/25 6/32 3.0 % 0.64 [ 0.18, 2.31 ]
Mendenhall 1977 4/12 2/17 2.2 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 34/90 35/88 13.4 % 0.95 [ 0.66, 1.37 ]
Porter 1971 6/11 7/9 8.2 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 4.7 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 6/12 7/15 6.5 % 1.07 [ 0.49, 2.34 ]
Theodossi 1982 17/28 19/32 12.4 % 1.02 [ 0.68, 1.55 ]
Thursz 2015 145/551 209/552 17.5 % 0.70 [ 0.58, 0.83 ]
Total (95% CI) 927 934 100.0 % 0.82 [ 0.64, 1.05 ]
Total events: 258 (Glucocorticosteroids), 351 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.08; Chi2 = 26.28, df = 14 (P = 0.02); I2 =47%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Sensitivity analysis: all-cause mortality, Outcome 2 Worst-best scenario
analysis: all-cause mortality up to 3 months’ follow-up after randomisation.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 3 Sensitivity analysis: all-cause mortality
Outcome: 2 Worst-best scenario analysis: all-cause mortality up to 3 months’ follow-up after randomisation
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Helman 1971 1/20 6/17 2.3 % 0.14 [ 0.02, 1.06 ]
Porter 1971 6/11 7/9 2.8 % 0.70 [ 0.37, 1.33 ]
Campra 1973 8/22 10/28 3.2 % 1.02 [ 0.48, 2.14 ]
Mendenhall 1977 4/12 2/17 0.6 % 2.83 [ 0.61, 13.06 ]
Blitzer 1977 11/17 5/16 1.9 % 2.07 [ 0.92, 4.64 ]
Shumaker 1978 6/12 7/15 2.2 % 1.07 [ 0.49, 2.34 ]
Maddrey 1978 3/25 6/32 1.9 % 0.64 [ 0.18, 2.31 ]
Depew 1980 8/15 7/13 2.7 % 0.99 [ 0.50, 1.98 ]
Theodossi 1982 18/28 16/32 5.4 % 1.29 [ 0.83, 2.00 ]
Mendenhall 1984 34/90 35/88 12.7 % 0.95 [ 0.66, 1.37 ]
Bories 1987 4/24 5/21 1.9 % 0.70 [ 0.22, 2.27 ]
Carithers 1989 4/36 11/31 4.2 % 0.31 [ 0.11, 0.88 ]
Ramond 1992 5/33 16/32 5.8 % 0.30 [ 0.13, 0.73 ]
Thursz 2015 212/551 141/552 50.6 % 1.51 [ 1.26, 1.80 ]
De 2014 10/31 5/31 1.8 % 2.00 [ 0.77, 5.18 ]
Total (95% CI) 927 934 100.0 % 1.21 [ 1.06, 1.37 ]
Total events: 334 (Glucocorticosteroids), 279 (Placebo/no intervention)
Heterogeneity: Chi2 = 37.13, df = 14 (P = 0.00070); I2 =62%
Test for overall effect: Z = 2.83 (P = 0.0047)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Sensitivity analysis: serious adverse events, Outcome 1 Best-worse scenario of
serious adverse events during treatment.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 4 Sensitivity analysis: serious adverse events
Outcome: 1 Best-worse scenario of serious adverse events during treatment
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blitzer 1977 8/17 5/16 3.9 % 1.51 [ 0.62, 3.65 ]
Bories 1987 4/24 2/21 1.3 % 1.75 [ 0.36, 8.61 ]
Campra 1973 7/22 10/28 4.8 % 0.89 [ 0.41, 1.96 ]
Carithers 1989 5/36 12/31 3.6 % 0.36 [ 0.14, 0.91 ]
De 2014 9/31 7/31 4.2 % 1.29 [ 0.55, 3.02 ]
Depew 1980 11/15 8/13 8.9 % 1.19 [ 0.70, 2.02 ]
Helman 1971 9/20 6/17 4.6 % 1.28 [ 0.57, 2.85 ]
Maddrey 1978 4/25 6/32 2.4 % 0.85 [ 0.27, 2.70 ]
Mendenhall 1977 4/12 2/17 1.4 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 18/90 16/88 7.3 % 1.10 [ 0.60, 2.02 ]
Porter 1971 6/11 7/9 6.7 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 4/33 16/32 3.3 % 0.24 [ 0.09, 0.65 ]
Shumaker 1978 8/12 9/15 7.9 % 1.11 [ 0.63, 1.97 ]
Theodossi 1982 20/28 19/32 13.8 % 1.20 [ 0.83, 1.74 ]
Thursz 2015 244/551 242/552 25.9 % 1.01 [ 0.88, 1.15 ]
Total (95% CI) 927 934 100.0 % 1.00 [ 0.83, 1.21 ]
Total events: 361 (Glucocorticosteroids), 367 (Placebo/no intervention)
Heterogeneity: Tau2 = 0.03; Chi2 = 19.54, df = 14 (P = 0.15); I2 =28%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Sensitivity analysis: serious adverse events, Outcome 2 Worst-best scenario of
serious adverse events during treatment.
Review: Glucocorticosteroids for people with alcoholic hepatitis
Comparison: 4 Sensitivity analysis: serious adverse events
Outcome: 2 Worst-best scenario of serious adverse events during treatment
Study or subgroup Glucocorticosteroids
Placebo/no
intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blitzer 1977 11/17 5/16 1.5 % 2.07 [ 0.92, 4.64 ]
Bories 1987 4/24 2/21 0.6 % 1.75 [ 0.36, 8.61 ]
Campra 1973 8/22 10/28 2.6 % 1.02 [ 0.48, 2.14 ]
Carithers 1989 7/36 12/31 3.8 % 0.50 [ 0.23, 1.12 ]
De 2014 10/31 6/31 1.8 % 1.67 [ 0.69, 4.02 ]
Depew 1980 11/15 8/13 2.5 % 1.19 [ 0.70, 2.02 ]
Helman 1971 9/20 6/17 1.9 % 1.28 [ 0.57, 2.85 ]
Maddrey 1978 4/25 6/32 1.6 % 0.85 [ 0.27, 2.70 ]
Mendenhall 1977 4/12 2/17 0.5 % 2.83 [ 0.61, 13.06 ]
Mendenhall 1984 18/90 16/88 4.8 % 1.10 [ 0.60, 2.02 ]
Porter 1971 6/11 7/9 2.3 % 0.70 [ 0.37, 1.33 ]
Ramond 1992 5/33 16/32 4.8 % 0.30 [ 0.13, 0.73 ]
Shumaker 1978 8/12 9/15 2.4 % 1.11 [ 0.63, 1.97 ]
Theodossi 1982 21/28 16/32 4.4 % 1.50 [ 1.00, 2.25 ]
Thursz 2015 269/551 217/552 64.4 % 1.24 [ 1.09, 1.42 ]
Total (95% CI) 927 934 100.0 % 1.18 [ 1.05, 1.31 ]
Total events: 395 (Glucocorticosteroids), 338 (Placebo/no intervention)
Heterogeneity: Chi2 = 22.56, df = 14 (P = 0.07); I2 =38%
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Number of participants with most often occurring serious adverse events during treatment
Trial Gastrointestinal
haemorrhage
Hepatorenal syndrome
(with or without hep-
atic failure)
Septicaemia Hepatocellular carcinoma
Pred-
nisolone
Control Pred-
nisolone
Control Prednisolone Control Prednisolone Control
Helman
1971
- - - 3 - - - -
Porter 1971 4 2 - - - - - -
Campra
1973
3 5 - 4 - - - -
Blitzer 1977 3 2 - 2 2 fungal - - 1
Mendenhall
1977
Not
reported
- - - - - - -
Maddrey
1978
1 1 3 6 - - - -
Shumaker
1978
3 3 - - 2 - -
Depew
1980
2 1 - - 2 1 - -
Theodossi
1982
11 6 - - 7 6 - -
Bories 1987 3 3 - 2 - - - -
Carithers
1989
2 4 - - 1 - - -
Mendenhall
1984
- - - - - - - 2
Ramond
1992
1 2 - - 1 1 - -
De 2014 2 3 3 - 3 1 - -
Richardet 1993 is missing from the table as no data were provided for quantitative analysis.
For Thursz 2015, see Table 2.
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Table 2. Most often occurring serious adverse events in Thursz trial: number of events
Type of adverse event Prednisolone group Control group
Gastrointestinal haemorrhage plus
variceal bleeding
40 28
Infections 74 43
- lung 38 17
- sepsis 14 14
A P P E N D I C E S
Appendix 1. Search strategies
Database Search performed Search strategy
CochraneHepato-BiliaryControlledTrials
Register
January 2019 (glucocortico* or steroid* or dexamethasone or prednis* or hy-
drocortisone or corticosteroid* or cortiso* or budesonide* or
beclomethasone*) AND (alcohol* and (liver or hepati*))
Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Li-
brary
Issue 1, 2019 #1 MeSH descriptor: [Adrenal Cortex Hormones] explode all
trees
#2 (glucocortico* or steroid* or dexamethasone or prednis* or
hydrocortisone or corticosteroid* or cortiso* or budesonide* or
beclomethasone*)
#3 #1 or #2
#4 MeSH descriptor: [Hepatitis, Alcoholic] explode all trees
#5 (alcohol* and (liver or hepati*))
#6 #4 or #5
#7 #3 and #6
MEDLINE Ovid 1946 to January 2019 1. exp Adrenal Cortex Hormones/
2. (glucocortico* or steroid* or dexamethasone or prednis* or
hydrocortisone or corticosteroid* or cortiso* or budesonide* or
beclomethasone*).mp. [mp=title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease sup-
plementary concept word, unique identifier]
3. 1 or 2
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(Continued)
4. exp Hepatitis, Alcoholic/
5. (alcohol* and (liver or hepati*)).mp. [mp=title, abstract, orig-
inal title, name of substance word, subject heading word, key-
word heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier]
6. 4 or 5
7. 3 and 6
8. (random* or blind* or placebo* or meta-analys*).mp. [mp=
title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplemen-
tary concept word, rare disease supplementary concept word,
unique identifier]
9. 7 and 8
Embase Ovid 1974 to January 2019 1. exp corticosteroid/
2. (glucocortico* or steroid* or dexamethasone or prednis* or
hydrocortisone or corticosteroid* or cortiso* or budesonide* or
beclomethasone*).mp. [mp=title, abstract, heading word, drug
trade name, original title, device manufacturer, drug manufac-
turer, device trade name, keyword]
3. 1 or 2
4. exp alcohol liver disease/
5. (alcohol* and (liver or hepati*)).mp. [mp=title, abstract,
heading word, drug trade name, original title, device manufac-
turer, drug manufacturer, device trade name, keyword]
6. 4 or 5
7. 3 and 6
8. (random* or blind* or placebo* or meta-analys*).mp. [mp=
title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name,
keyword]
9. 7 and 8
Science Citation Index Expanded (Web of
Science)
1900 to January 2019 #5 217 #4 AND #3
#4 1,347,943 TS=(random* or blind* or placebo* or meta-
analys*)
#3 1,060 #2 AND #1
#2 36,574 TS=(alcohol* and (liver or hepati*))
#1 425,242 TS=(glucocortico* or steroid* or dexamethasone
or prednis* or hydrocortisone or corticosteroid* or cortiso* or
budesonide* or beclomethasone*)
eLibrary 1999 to January 2019 (glucocortico* or steroid* or dexamethasone or prednis* or hy-
drocortisone or corticosteroid* or budesonide*) AND (alco-
hol* and (liver or hepati*))
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Appendix 2. Level of liver enzymes (at the end of treatment)
Study Glucocorticosteroids Placebo/no intervention
Mean SD n Mean SD n
Campra 1973 62.5 3.72 22 79.2 5.83 28
Maddrey 1978 34.5 4 23 41.7 4.1 27
Theodossi 1982 164.0 - 28 118 - 32
Carithers 1989 74.9 4.19 36 119.9 7.79 31
-: data not reported; n: number of participants; SD: standard deviation
Appendix 3. Prothrombin index (seconds)
Study Glucocorticosteroids Placebo/no intervention
Mean SD n Mean SD n
Percentage of normal
Campra 1973 77.5 2.5 36 83.1 2 31
Ramond 1992 48 0.5 32 45 0.5 29
At the end of treatment
Maddrey 1978 14 0.5 23 15.5 0.9 27
Theodossi 1982 13 - 28 10 - 32
Carithers 1989 15.5 1.25 36 16.25 1 31
-: data not reported; n: number of participants; SD: standard deviation
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Appendix 4. Level of serum albumin (g/L)
Study Glucocorticosteroids Placebo/no intervention
Mean SD n Mean SD n
Campra 1973 33.3 1.48 22 30.08 0.66 28
Maddrey 1978 33 2 23 30 2 27
Depew 1980 32 0.17 15 25.8 0.13 13
Carithers 1989 27 0.35 36 29 0.4 31
Ramond 1992 33 0.17 32 30 0.37 29
n: number of participants; SD: standard deviation.
Appendix 5. Level of bilirubin (µmol/L) (at the end of treatment)
Study Glucocorticosteroids Placebo/no intervention
Mean SD n Mean SD n
Campra 1973 43.2 2.9 22 63.95 6.84 28
Maddrey 1978 64.98 4.97 24 66.69 3.69 31
Depew 1980 68.4 6.5 15 136.8 11.79 13
Carithers 1989 125 8.12 36 190 17.9 31
Ramond 1992 100 7.1 32 150 18.8 29
n: number of participants; SD: standard deviation
Appendix 6. Age (years)
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Study Glucocorticosteroids Placebo/no intervention
Mean SD n Mean SD n
Porter 1971 44.6 4.4 11 49.5 8.9 9
Campra 1973 43.1 11.1 22 42.7 8.1 28
Blitzer 1977 47.2 - 17 48.4 - 16
Maddrey 1978 40 8.5 25 42.3 11.1 32
Shumaker 1978 45.5 - 15 44.5 - 13
Depew 1980 49.8 2.1 15 48.2 2.3 13
Mendenhall
1984
51.5 8.2 90 50.4 9.2 88
Bories 1987 41 - 24 49 - 21
Carithers 1989 43.1 2 36 44.4 1.7 31
Ramond 1992 48.1 1.3 33 48.2 1.6 32
De 2014 42.7 0.4 31 41.3 7.8 31
Thursz 2015 48.6 9.8 277 47.9 9.2 276
Thursz 2015 49.3 10.6 274 48.8 10.3 276
-: data not reported; n: number of participants; SD: standard deviation
WH A T ’ S N E W
Date Event Description
19 February 2019 New search has been performed We have revised the whole review so that it reflects
current Cochrane methodology
We have excluded evaluation of imprecision with Trial
Sequential Analysis from the GRADE assessment. In
the previously published review, assessment of impre-
cision with Trial Sequential Analysis was presented in
the ’Summary of findings’ table
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(Continued)
28 January 2019 New citation required but conclusions have not
changed
No new randomised clinical trials identified for the re-
view update
Discrepancies occurred in GRADE assessment and in
conclusions in certainty of evidence for the outcomes:
serious adverse events (from low to very low); liver-re-
lated mortality up to three months following randomi-
sation (from low to very low); and any complication,
up to three months following randomisation (from low
to very low)
28 January 2019 New search has been performed Search for new trials performed 18 January 2019
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External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• Review author team changed.
• We removed the word ’alcohol’ from the outcome “Alcohol liver-related mortality up to three months’ follow-up after end of
treatment” as it was superfluous.
• Outcomes
◦ All-cause mortality is now better defined. Duration of treatment varied across the trials and also mortality data for up to
three-months’ follow-up. This is why we have modified all-cause mortality to all-cause mortality at the end of treatment, up to three
months’ follow-up after randomisation, and one year following randomisation. Thus, our primary time point has become “all-cause
mortality up to three months’ follow-up after randomisation.”
◦ Trials also reported data on liver-related mortality, any complication, and non-serious adverse events up to three months’
follow-up after randomisation. Thus, three months’ follow-up after randomisation has also become our primary time point for the
latter outcomes. However, serious adverse events were reported mostly during the treatment period.
◦ Regarding exploratory outcomes, we created tables, as we did not have sufficient data for analysis.
• Originally we wrote in the protocol that “We will consider trials published before or after 1989 carefully, as the Maddrey’s score
was modified in 1989 in order to stratify severe alcoholic hepatitis and define the group of people to be treated.” However, it made
also sense to use the definitions of the trialists for mild and severe alcoholic hepatitis and we wrote: “For studies not reporting the
Maddrey’s score, we used the classifications for mild and severe alcoholic hepatitis as provided by the trialists.”
• As we did not have trials at low risk of bias, we calculated the diversity-adjusted required information size (DARIS) for our Trial
Sequential Analysis using data from all included trials.
• We calculated and reported the Trial Sequential Analysis-adjusted CI as a supplement to the naive 95% CI.
• We changed the risk of type I error from 2.5% (as originally planned based due to the three primary outcomes) into type I error
of 1%, as we performed Trial Sequential Analysis on all primary and secondary outcomes, including post-hoc time points.
Differences between previously published review version and this version
• ’Quality of evidence’ was modified into ’certainty of evidence.’
• As per current Cochrane recommendations, we were advised to keep in separate assessments of imprecision with Trial Sequential
Analysis and GRADE in the ’Summary of findings’ table. Therefore, we assessed imprecision with Trial Sequential Analysis and
GRADE as sensitivity analysis.
• Serious adverse events during treatment; liver-related mortality up to three months following randomisation; and number of
participants with any complications up to three months following randomisation in the GRADE ’Summary of findings’ table.
• As per current Cochrane recommendations, we were advised not to include ’for-profit bias’ risk domain in the overall bias risk
assessment tool. Therefore, we removed the domain. We planned to perform a subgroup analysis with trials without for-profit
funding compared to trials at risk of for-profit funding instead. However, only one trial seemed not be industry funded and the
remaining trials did not clearly report on industry funding.
• We performed a subgroup analysis on risk of bias (only one trial (Thursz 2015) fell into the group of trials at low risk of bias).
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N O T E S
Cochrane Reviews can be expected to have a high percentage of overlap in the methods section because of standardised methods. In
addition, overlap may be observed across two of our protocols as they share at least four common authors.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Glucocorticoids [adverse effects; ∗therapeutic use]; Hepatitis, Alcoholic [∗drug therapy; mortality]; Quality of Life; Randomized
Controlled Trials as Topic
MeSH check words
Adult; Aged; Female; Humans; Male; Middle Aged
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